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    SUMMARY 
Post-translational modifications of NF-κB via phosphorylations enhance the 
transactivation potential of NF-κB. Much is known about the kinases that phosphorylate 
NF-κB, but little is known about the phosphatases that dephosphorylate NF-κB. Here, we 
report the regulation of NF-κB by the WIP1 phosphatase and its role in inflammation. 
Overexpression of WIP1 in HeLa cervical cancer and Saos-2 osteoscarcoma cells results 
in decreased NF-κB activation in a manner dependent on the dosage of WIP1. 
Overexpression of WIP1 could also repress the expression of endogenous NF-κB target 
genes in response to inflammatory stimuli. Conversely, knockdown of WIP1 results in 
increased NF-κB transcriptional function.  
To investigate the molecular mechanism by which WIP1 regulates NF-κB 
function, we investigated whether WIP1 can dephosphorylate any component of the NF-
κB signaling cascade. Using in vitro and in vivo experiments, we demonstrate that WIP1 
is a direct phosphatase on serine 536 of the p65 subunit of NF-κB. The phoshorylation of 
p65 on serine 536, is known to be critical for the transactivation function of p65 since the 
phosphorylation of p65 is required for the recruitment of transcriptional co-activator p300 
to aid in full transcriptional activity of p65. 
    Since WIP1 can dephosphorylate p38 mitogen-activated protein kinase 
(MAPK), and p38 MAPK is known to regulate p65 through direct/indirect 
phosphorylation, we investigated the possibility of WIP1 affecting NF-κB through p38 
MAPK. The addition of a specific p38 MAPK inhibitor (SB202190) did not decrease the 
Summary viii
phosphorylation status of p65 on serine 536, nor did it affect the expression of a subset of 
NF-κB target genes in HeLa WIP1siRNA cells. We thus propose that WIP1 is part of the 
NF-κB signaling pathway, and has a role in negatively regulating a subset of NF-κB 
target genes in a p38 MAPK independent manner.   
Post-translational modification of the histones surrounding NF-κB target genes 
has a key role in modulating cancer and inflammation. Chromatin remodeling must 
happen for the accessibility of transcription factors and the replication machinery to gene 
promoters of the cell. Inappropriate expression of genes due to altered chromatin 
structure has been implicated in tumourigenesis. Inhibiting the activity of histone 
deacetylases (HDACs) using HDAC inhibitors, can induce histone hyperacetylation, 
reactivate transcriptionally silenced genes, resulting in cell cycle arrest and apoptosis. 
The growth and survival of tumour cells are inhibited, while leaving untransformed cells 
relatively intact.  
Through microarray analysis, we identified several mRNA of NF-κB associated 
genes in inflammation, for example, lymphotoxin β receptor (LTβR), interleukin-2 
receptor (IL-2R), NF-κB1, and adaptor protein interleukin-1 receptor-associated kinase 1 
(IRAK1), to be down-regulated when human cancer cells are treated with HDAC 
inhibitor, trichostatin A (TSA). We also identified genes involved in apoptosis, of 
particular interest, clusterin, which has a proapoptotic role via relief of histone 
deacetylase inhibition. Therefore, we propose HDAC inhibitors are good therapeutics for 
treatment of cancer, and malignancies associated with inflammation because they can 
Summary ix
regulate NF-κB associated genes in inflammation through chromatin remodeling. By 
reducing cytokine expression, HDAC inhibitor can inhibit tumour growth. 
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1.1 Apoptosis in cancer 
 Intensive research effort has been focused on understanding cancer biology and 
cancer genetics that drive the progressive transformation of normal human cells into 
highly malignant cancer cells. The tumourigenic process of a normal cell to a cancer cell 
has been described into three phases: 1) tumour initiation, 2) tumour promotion, 3) 
tumour invasion and metastasis (Karin and Greten, 2005). In the first phase of  
tumourigenesis, the DNA of a normal cell becomes mutated by physical and chemical 
carcinogens, leading to the activation of oncogenes or the inactivation of the tumour 
suppressor genes, where the normal cell eventually develop into a cancerous cell. In the 
second phase of tumour promotion, inflammatory cytokines such as interleukin-1 (IL-1) 
and tumour necrosis factor (TNF) has been observed to promote the proliferation and 
clonal expansion of initiated cancerous cells. In the final phase of tumourigenesis, the 
tumour increase in size (or growth), and acquire more mutations, leading to a more 
malignant phenotype. 
  The ability of cancer cells to expand in numbers is not only determined by the 
rate of proliferation, but dependent on the rate of elimination of cancerous cells by 
apoptosis. Apoptosis or “physiological cell death” was described by its morphological 
characteristics, such as cell shrinkage, membrane blebbing, chromatin condensation and 
nuclear fragmentation which are engulfed by phagocytic cells (Wyllie et al., 1980). A 
variety of signals that can trigger apoptosis in cells include growth/survival factor 
depletion, hypoxia, UV radiation, and DNA damage (cell-cycle checkpoint defects) and 
chemotherapeutic drugs (Lowe and Lin, 2000). 
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 Like metabolism or development, the inherent apoptotic program can be disrupted 
by genetic mutations in cancer-related genes that disrupt or promote apoptosis. These 
genes were classified as oncogenes with dominant gain of function or tumour suppressor 
genes with recessive loss of function in tumour development. One example of such loss 
of function of a tumour suppressor gene is p53, which is often found to be mutated or 
deleted in cancer. The antiproliferative effect of p53 in response to cellular stresses is 
exhibited in cell cycle progression. p53 prevents a damaged cell from dividing before 
completion of DNA repair, and prevent the cell from becoming cancerous (Lane, 2005). 
The importance of p53 proapoptotic function is demonstrated in mouse thymocytes 
where the presence of p53 in these thymocytes induced cell death in response to radiation 
(Lowe et al., 1993). On the other end of the spectrum, the gain of function of the 
oncogene Bcl2 promote cancer. Its antiapoptotic effect was shown in transgenic mice, 
whereby the overexpression of Bcl2 promoted extended B cell survival and 
lymphoproliferation (McDonnell et al., 1989). Given the above examples of how 
oncogenic or tumour suppressor genes can disrupt the process of apoptosis, the loss of 
apoptotic program in cells can promote tumour progression, invasion and metastasis. 
1.2 Mechanism of apoptosis  
 Despite the cellular diversity of our body, all cells appear to activate the basic 
apoptotic program upon external trigger. Two major pathways have been indentified, 
namely the “extrinsic” and the “intrinsic” pathways (Figure 1.1). The extrinsic pathway is 
triggered through the ligation of specific cell-death surface receptors (TNF, TRAIL and 
FasL), whereas the intrinsic pathway is dependent on mitochondrial membrane 
permeabilization which releases apoptogenic factors into the intermembrane space of the 
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cytoplasm. The eventual consequences of both pathways are similar as they both 
converge on the activation of key effectors of apoptosis-the caspases. Once activated, 
caspases cleave cellular substrates (Luthi and Martin, 2007), including lamins, kinases, 
and proteins involved in DNA replication, cell survival and mRNA splicing, resulting in 
morphological cell death known as apoptosis. Generally, it is believed that the “extrinsic” 
pathway is activated by immune-mediated signals, while the “intrinsic” pathway is 
engaged by cellular stresses.  
 Regulators of apoptosis exist in the mammalian cells to switch cells to the “death 
mode” or to remain alive in the event of cancer. The B-cell CLL/lymphoma 2 (Bcl2) 
family constitutes a major family of cell death regulators which have either proapoptotic 
or antiapoptotic effects. The proapoptotic members of Bcl2 family such as Bcl2-
associated X protein (Bax), Bcl2 antagonist killer 1 (Bak), and BH3-interacting domain 
death agonist (Bid) promote cytochrome-c release from the mitochondria while the 
overexpression of the antiapoptotic molecule Bcl2 block cytochrome-c release (Yang et 
al., 1997). The release of cytochrome c from the mitochondria is necessary in the 
formation of the apoptotic protease activating factor 1(Apaf-1)/cytochrome-c complex 
(Li et al., 1997), which mediates the activation of initiator caspase-9. Activated caspase-9 
cleaves procaspase-3 to activated caspase-3 which is responsible for the cleavage of 
DNA, and the morphological changes observed in cells undergoing apoptosis. It was 
proposed that the Bcl2 family of proteins can in turn regulate each other by binding to 
one another. The antiapoptotic proteins Bcl2, Bcl2-related protein, long isoform, included 
(Bcl-XL), Bcl2-like2 (BcL-W), myeloid cell leukemia 1 (Mcl-1) and Bcl2-related protein 
A1 (A1) act on the outer mitochondrial membrane by neutralizing the killer proteins Bax 
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and Bak, and following death triggers, Bax and Bak are liberated from Bcl-2 mediated 
inhibition by BH3-only proteins like Bcl2-interacting protein Bim (Bim), Bid, Bcl2 
antagonist of cell death (Bad), Puma, Noxa, Bcl2-modifying factor (Bmf), harakiri (Hrk), 
and Bcl2-interacting killer (Bik) (Willis et al., 2007; Letai et al., 2002). The details of 
how this Bcl-2 family of proteins function and how their dynamics influence cell fate is 
unclear, and an area of intense debate. 
 Activation of apoptosis does not always lead to cell death. Inhibitor of Apoptosis 
(IAP) is another group of regulatory proteins that are able to bind to and inhibit caspases. 
The mammalian IAP, inhibitor of apoptosis, X-linked (XIAP) is a potent physiological 
inhibitor of caspase-3, caspase-7 and capase-9, and its capability to bind to caspase-3 and 
7 lies in the baculoviral IAP repeat 2 (BIR2) domain, while its BIR3 domain binds to 
caspase-9, which occludes substrate entry on the caspases and hence the inhibition of the 
caspase’s catalytic activity (Silke et al., 2002). Cells that are fated to die overcome the 
IAP-mediated inhibition through a specialized group of IAP antagonists, Second 
mitochondria-derived activator of caspase (Smac) or Direct IAP-binding protein with low 
pI (DIABLO), that are released into the cytosol, alongside with apoptogenic factors like 
cytochrome-c upon death stimuli. When Smac/DIABLO is released into the cytosol, 
promotes apoptosis by binding to XIAP, and remove the inhibitory effect of XIAP on 
caspase-3 and caspase-9, thus liberating caspases to execute apoptosis (Verhagen et al., 
2000). Smac/DIABLO can therefore circumvent the effect of IAPs and are good 
therapeutic targets in cancer. 
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Figure 1.1: The extrinsic and intrinsic pathways of caspase activation and apoptosis 
The extrinsic pathway involves oligomerization of death receptors by their ligands, 
resulting in the recruitment and activation of initiator caspases which directly execute 
apoptosis by cleaving Bid which then translocate to the mitochondria to initiate the 
intrinsic pathway, or the cleavage and activation of caspase-3. The intrinsic pathway is 
activated by the proapoptotic Bcl2 family of proteins which triggers mitochondrial 
release of apoptogenic factors like cytochrome-c into the cytosol, necessary in the 
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1.3 Transcription factor NF-κB  
 Transcription factors influence cells’ decision to undergo apoptosis by activating 
the transcription of genes involved in apoptosis. Nuclear factor kappa B (NF-κB) is one 
such transcription factor believed to have an antiapoptotic effect in cancer cells, while 
tumor suppressor p53 is another transcription factor which has a proapoptotic effect. The 
transcriptional targets of p53 include the Bcl2 family of proapoptotic proteins such as 
p53-upregulated modulator of apoptosis (PUMA) and NOXA (for “damage”), which 
function by inducing the loss of inner mitochondrial membrane potential, leading to the 
release of cytochrome-c and apoptogenic factors and the activation of the caspase cascade 
that results in apoptotic cell death (Villunger et al., 2003). NF-κB acts in opposition to 
p53, and has a proliferative effect in cells by activating the expression of antiapoptotic 
genes like Bcl-XL, cIAP1, cIAP2 and XIAP (Pahl, 1999). NF-κB and p53 play pivotal 
role in deciding cell fate because NF-κB mediated upregulation of antiapoptotic gene 
targets can antagonize the proapoptotic function of p53 (Tergaonkar and Perkins, 2007). 
 NF-κB is discovered by Sen and Baltimore to be a protein that binds to specific 
DNA sequences (5’-GGGACTTTCC-3’) also known as κB sites, of the immunoglobulin 
kappa light chain gene in mature B and plasma cells (Sen and Baltimore, 1986). NF-κB 
was shown to exist and expressed in many cell types. In the majority of cell types, NF-κB 
exists in the cytoplasm as a complex with inhibitor of kappa light chain gene enhancer in 
B cells (IκB) in quiescent cells. Mammalian cells express 5 members of the NF-κB 
members of protein (Figure 1.2), RELA, RELB, c-REL, p105 and p100 (Hayden and 
Ghosh, 2008). The REL members can form hetero and homodimers among themselves 
except RELB, and by far the p65/p50 heterodimers is the most stable heterodimer seen in 
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all cell types. The REL members all contain a REL homology domain (RHD), in it which 
lies the DNA binding, dimerization and IκB binding domain. Of the five members, only 
RELA, RELB and c-REL has a transcription activation domain (TAD) necessary for gene 
expression. Both the RHD and TAD domain undergo post-translational modification that 
affect NF-κB transcription.  
The p100 and p105 function as inhibitors of NF-κB as they interact with other 
REL members, and they reside exclusively in the cytoplasm, and prevent NF-κB into the 
nucleus to activate transcription. p100 and p105 are processed through distinct 
mechanism to p52 and p50 respectively (Lin et al., 1998; Xiao et al., 2001). p50 and p52 
form hetero or homodimers, bind to κB consensus sites on DNA, and hence may act as 
transcriptional co-repressors, unless they form heterodimers with any of the TAD-
containing NF-κB family members. Therefore, whether the REL family of transcription 
factors functions as co-activator or co-repressor depend on its subcellular localization, 
and if they contain a TAD domain. 
Gene knockout mouse models for all the five members of NF-κB family of 
protein have been generated by homologous recombination in mice. These knockout 
mouse models reveal the different roles of each NF-κB proteins in regulating immune 
response in mammals (Li and Verma, 2002). p65 knockout mice have massive TNF-
dependent liver apoptosis, and are embryonic lethal at E15.5-E16.5, indicating an 
important role of p65 in development. Mice lacking NF-κB1, NF-κB2 and c-REL have 
defects in lymphocyte activation, while RELB knockout mice die postnatally from multi-
organ inflammation. In addition, RELB is required for dendritic-cell development. Mice 
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lacking one of the five NF-κB members do not inherit development defects, but all 
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Figure 1.2: The family of mammalian NF-κB/REL proteins 
All seven mammalian REL-related proteins- RELA/p65, RELB, c-REL, p105, p100, p52 
and p50 contains REL homology domain necessary for DNA binding and IκB 
association. Only RELA, RELB, c-REL contain carboxy-terminal transactivation 
domains (TADs) essential for gene expression. The glycine-rich regions (GRR) domains 
are essential for co-translational processing of p105 to p50 and post-translational 
processing of p100 to p52. Phosphorylation of RELA at serines (S) 276, 311, 529 and 
536 is required for optimal NF-κB transcriptional activity. The 3 main sites of acetylation 
on RELA at (K) 218, 221, and 310/311 regulate NF-κB transcriptional activity, and IκBα 
association. The number of amino acids in each human protein is indicated on the right. 
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1.4 NF-κB in inflammatory diseases and cancer 
NF-κB plays a critical role in inflammation and innate immunity through 
proinflammatory cytokine receptor signaling via the Toll-like receptor (TLR), TNF 
receptor and IL-1 receptor (Karin, 2006).  In inflammatory cells, IKK1-dependent NF-κB 
pathway promotes tumour cells development through inducing the expression of genes 
encoding cytokines (IL-1 and TNFα) and growth factors (VEGF and CSF). These 
secreted cytokines and growth factors bind to the receptors expressed on adjacent tumour 
cell surface, and further promote clonal expansion of cancerous cells. In the case of the 
IL-1 and TNF cytokine, interaction of these cytokines to their respective receptors on the 
cancer cell activates downstream signaling components of the NF-κB pathway, which in 
turn activate NF-κB to bind to DNA promoter to transcribe antiapoptotic genes, ensuring 
tumourigenic cell survival and proliferation. 
Genetic evidence further support inflammation in tumour promotion, whereby 
polymorphism in the TLR gene cluster and IL-1β promoter are associated with high risk 
of prostate and gastric cancer respectively (Sun et al., 2005; El-Omar et al., 2000). 
Although the NF-κB activating cytokine TNF has been named according to its ability to 
induce tumour cells necrosis and to trigger apoptosis, TNF does not trigger cell death 
unless it is combined with RNA and protein synthesis inhibitor in cell treatment (Karin, 
2006). Enough scientific evidences exist to show that TNFα acts as a tumour promoter in 
skin and gastric cancer (Lind et al., 2004; Oshima et al., 2005). Moreover, activation of 
NF-κB has also been reported to be a tumour promoter in inflammation–associated 
cancer, namely colitis-associated cancer (CAC) and mucosal-associated lymphoid tissue 
Chapter 1 Introduction  12
(MALT), which further support its role in linking inflammation and immunity to cancer 
progression (Karin, 2006). 
1.5  NF-κB signaling pathway 
1.5.1 Signaling to NF-κB through the classical or “canonical” pathway 
The first phase of NF-κB activation occurs in the cytoplasm where NF-κB exists 
in the cytoplasm in an inactive form through its association with the IκB proteins in 
quiescence cells. IκBs are known to be inhibitors of NF-κB because IκB retains NF-κB in 
the cytoplasm by masking the nucleus localization sequence (NLS) on NF-κB subunits, 
thus preventing NF-κB translocation into the nucleus to activate gene transcription. These 
proteins are identified by the presence of ankyrin repeats which can be proteolytically 
cleaved and degraded. The IκB family of proteins consist of  IκBα, IκBβ, IκBε, IκBζ, 
IκBγ and B-cell leukemia/lymphoma 3 (BCL3), among the predominant ones are the 
IκBα, IκBβ and IκBε,  while the biological role of IκBγ is not very clear (Figure 1.3). 
Cells that lack IκBα, IκBβ and IκBε have normal nuclear and cytoplasmic distribution of 
p65 but significantly increased basal NF-κB dependent gene expression (Tergaonkar et 
al., 2005).  
The crystal structure of IκBα and the p65/p50 dimer reveals that IκBα only masks 
one of the two NLS on the heterodimer, which allows the NF-κB-IκBα complex to shuttle 
from the cytoplasm to the nucleus (Huxford et al., 1998). The nuclear export signal 
(NES) located on the N-terminus of  IκBα serve to constantly export the NF-κB-IκBα 
complex out of the nucleus, therefore the NF-κB-IκBα complex shuttle constantly 
between the cytoplasm and the nucleus, which leads to basal transcriptional activity of 
NF-κB in non-activated cells (Birbach et al., 2002). Similar to IκBα, IκBε also form a 
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complex with NF-κB to shuttle between the cytoplasm and nucleus (Lee and Hannink, 
2002). On the contrary, IκBβ masks both the NLS of the NF-κB dimer and retain the NF-
κB-IκBβ complex in the cytoplasm (Malek et al., 2001). 
Traditionally, the role of the IκB proteins functions as inhibitors of NF-κB. New 
scientific evidence have arised to show that IκBζ and BCL3 may act as co-activators of 
NF-κB. The IκBζ and p50 complex is found on the promoter of interleukin-6 (IL-6), an 
NF-κB target gene. The expression of IL-6 has not been found in IκBζ knockout cells, 
therefore suggesting that IκBζ is indispensable for the expression of IL-6 (Yamamoto et 
al., 2004). The co-activator function of BCL3 is not completely understood, and BCL3 is 
found to be associated with p50 and p52-containing homo and heterodimers in the 
nucleus, and may function to displace the repressive effect of  p50 and p52 dimers from 
the κB sites so that other TAD-containing dimers can bind to the κB sites (Hayden and 
Ghosh, 2004; Perkins, 2006). Therefore, the repressor function of IκBs has been 
challenged, as more evidence show that some members of the IκB family of proteins can 
function as co-activators. 
NF-κB signaling is generally considered to occur through either the classical or 
alternative pathway (Bonizzi and Karin, 2004). It is widely accepted that the classical 
pathway is essential for innate immunity because it coordinate the expression of a subset 
of genes (such as IL-6, IL-8, TNFα), involved in inflammation and innate immunity 
(Bonizzi and Karin, 2004). In the classical pathway, NF-κB is activated through 
cytokines, such as IL-1, TNFα, and bacteria cell wall lipopolysaccharide (LPS), which 
bind to their cell surface receptors IL-1 receptor, TNFα receptor and Toll-like receptor 4 
(TLR4) respectively. TLRs are evolutionarily conserved pattern recognition receptors 
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(PRRs) that recognize conserved pathogen-associated microbial patterns (PAMPs) 
present on various microbes (Kopp and Medzhitov, 2003). 
These extracellular cytokines and LPS bind to their respective receptors and 
employ various different intermediate upstream signaling molecules which converge on 
the 700-900kDa IKK complex (Chen et al., 1996), consisting of IKKα (IKK1), IKKβ 
(IKK2) and NF-κB essential modifier (NEMO) or IKKγ, to phosphorylate IκBα (Figure 
1.4) to release NF-κB from its inhibitor. NEMO has no intrinsic kinase activity but 
contains a helix-loop-helix and leucine zipper motif known for protein-protein 
interaction. Upon interaction with upstream signal transduction molecule such as receptor 
interacting protein kinase 1 (RIPK1), NEMO oligomerizes which in turn activates the 
IKK1 and IKK2 (Poyet et al., 2000), resulting in the auto-phosphorylation of IKK via the 
T loop serine residues, serine 177 and 181 within the activation loop of the IKK kinase 
domain (Hacker and Karin, 2006). Activated IKK2 in turn phosphorylates IκBα leading 
to its ubiquitination by βTrCP proteins and degradation by the 26S proteosome. The 
importance of the IKK complex in NF-κB activation is shown in murine embryonic 
fibroblast (MEF) cells lacking both IKK1 and IKK2 or NEMO alone, whereby NF-κB 
activation is completely blocked in these knockout MEF (Li et al., 2000; Rudolph et al., 
2000).   
The classical pathway selectively utilizes IKK2 to phosphorylate IκBα on serine 
32 and 36, and IκBβ on serine 19 and serine 23, leading to its ubiquitination by βTrCP 
proteins and degradation by the 26S proteosome, and the release of NF-κB from the NF-
κB-IκB complex (Karin and Ben-Neriah, 2000; Ben-Neriah, 2002), to translocate to the 
nucleus to activate gene transcription. Upon phosphorylation by IKKs, IκB proteins are 
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recognized, and ubiquitinated by members of the Skp1-Cullin-Roc1/Rbx1/Hrt-1-F-box 
(SCF or SCRF) family of ubiquitin ligases. βTrCP, the receptor subunit of the SCF 
family ubiquitin ligase machinery, binds directly to the phosphorylated E3 recognition 
sequence (DS*GXXS*) on IκBα (Suzuki et al., 1999). Recognition of IκBα leads to 
polyubiquitination at conserved residues, Lys 21 and Lys 22 on IκBα, by the SCFβ-TrCP 
and the E2 UbcH5 (Scherer et al., 1995), leading to its degradation. 
Signaling molecules immediately downstream of cell surface receptors are 
essential intermediate players to relay the message from the cell surface to the internal of 
the cell to activate the IKK complex. TNF receptors are present on the surface of a wide 
range of cells, and use a unique set of intermediate signaling protein component different 
from those that are used by the IL-1 and TLR4 receptors. The ligation of TNFα with its 
TNF receptor results in receptor trimerization and the recruitment of prosurvial complex 
consisting of adaptor protein TNF receptor associated via death domain (TRADD), TNF 
receptor associated protein 2 (TRAF2), RIPK1, cIAP1 and cIAP2 to the cytoplasmic 
receptor, which then recruits and activate the IKKs to phosphorylate IκBα (Jiang et al., 
1999; Bradley and Pober, 2001; Hsu et al., 1996).  
The activation of NF-κB through TNF signaling directly regulates the expression 
of antiapoptotic genes like Bcl-XL and XIAP. The interesting aspect of TNF signaling is 
its ability to stimulate death and survival through transcription factor NF-κB and Jun N-
terminal protein kinase (JNK), which it activates. The activation of NF-κB leads to 
survival of cells, while prolonged activation of JNK leads to apoptosis (Guo et al., 1998). 
It is proposed that XIAP induced by NF-κB blocks JNK activation (Tang et al., 2001), 
however the effects of JNK and NF-κB are not entirely antagonistic because the 
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expression of antiapoptotic cIAP protein is co-regulated by both NF-κB and JNK, and 
TNFα induced apoptosis is increased in JNK1 and JNK2 double-knockout cells (Lamb et 
al., 2003; Ventura et al., 2003). 
The IL-1 and TLR4 receptor share similar intermediate signaling protein 
components downstream of its receptors that converge on IKK to activate NF-κB. The 
IL-1 and TLR4 receptor bear strong homology in the intracellular domain and share a 
similar Toll-IL-1R (TIR) domain that interacts with downstream adapter, myeloid 
differentiation primary response gene 88 (MyD88) (Jassens and Beyaert, 2003). MyD88 
contains a death domain (DD) that interacts with serine/threonine kinase IRAK1 and 
IRAK4 (Suzuki et al., 2002). IRAK activation and TNF receptor associated protein 6 
(TRAF6) recruitment to the signaling complex by IRAK is necessary to activate NF-κB 
because TRAF6 deficient cells has a complete loss of NF-κB transcriptional activity in 
IL-1 and TLR4 signaling (Lomaga et al., 1999).  
The protein that link TRAF6 to IKK activation has remained controversial. Two 
adaptor proteins have been speculated to link TRAF6 and IKK. The first set of proteins 
described to be linking TRAF6 and IKK, are transformining growth β activated kinase 1 
(TAK1), TAK1-binding protein 1 (TAB1) and TAK1-binding protein 2 (TAB2) (Wang et 
al., 2001). The TAK1, TAB1 and TAB2 protein complex could be co-purified with 
TRAF6. RNAi mediated knock down of TAK1 inhibited signaling from the IL-1 receptor 
(Takaesu et al., 2003), and hence demonstrated an essential role of TAK1 in IL-1 
signaling. However, the roles of TAB1 and TAB2 are unclear because TAB1 and TAB2 
knockout MEF exhibit normal IL-1 signaling (Sanjo et al., 2003). The second proposed 
adapter protein that connects TRAF6 and IKK is the evolutionarily conserved signaling 
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intermediate in toll pathways (ECSIT) protein. Through yeast two-hybrid screening, 
ECSIT was identified to be a binding partner of TRAF6, and RNAi-mediated knock 
















Chapter 1 Introduction  18







    
Figure 1.3 The family of mammalian IκB proteins 
The family of IκB proteins consists of the IκBα, IκBβ, IκBε, IκBγ, BCL3 and IκBζ. A 
unique characteristic of these proteins is that they contain ankyrin-repeat domain that 
mediate interaction with NF-κB and localize NF-κB in the cytoplasm by masking the 
nuclear localization signal (NLS) of NF-κB. Phosphorylation of IκBα on serine 32 and 
serine 36 triggers its polyubiquitination and proteosome-mediated degradation, freeing 
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Figure 1.4 Activation of the NF-κB pathway 
In the classical NF-κB pathway, NF-κB is activated after cellular activation by TNFα, 
LPS or IL-1. The IKK complex consist of IKK1 (IKKα), IKK2 (IKKβ) and NEMO 
(IKKγ). The IKK2 serve as the principal IκBα kinase in the classical pathway. In the 
alternative pathway, BAFF and CD40 activates NIK and IKK1, IKK1 phosphorylates 
p100, leading to the processing of p100 by the 26S proteosome to generate the p52-
RELB heterodimers to activate transcription. (Reproduced with permission from Nature 
Reviews Molecular Cell Biology) (Chen and Greene, 2004) 
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1.5.2 Signaling to NF-κB through the alternative or “non-canonical” pathway 
NF-κB can also be activated through the “non-canonical” or alternative pathway 
through the ligation of CD40L, BAFF and lymphotoxin β (LTβ) to its CD40, BAFF and 
lymphotoxin β receptor (LTβR) respectively. The alternative pathway is unique in that 
sense that it does not require IKK2 or NEMO, but requires only IKK1. Upon receptor 
activation, NF-κB inducing kinase (NIK) phosphorylates IKK1, activated IKK1 in turn 
directly phosphorylate the heterodimer p100 in association with RELB, leading to 
processing of p100 by the proteosome to release the transcriptionally active p52:RELB 
dimer which translocate into the nucleus to activate gene transcription (Xiao et al., 2001; 
Xiao et al., 2004). However, the events that occur upstream of NIK is unclear. It is 
believed that the alternative pathway plays a chief role in the expression of a subset of 
genes (such as PNAd, GlyCAM-1), involved in the development and maintenance of 
secondary lymphoid organs (Bonizzi and Karin, 2004). 
1.5.3 Signaling to NF-κB through cell stress 
NF-κB has been shown to be activated through cell irradiation and DNA damage. 
The interesting aspect of this signaling is that it does not occur through the conventional 
initiating receptor ligation. Ionizing irradiation and UV irradiation that causes DNA 
damage has been shown to activate NF-κB through two distinct mechanisms (Li and 
Karin, 1998). In the clinical context, patients suffering from ataxia-telangiectasia (AT) 
have mutations in the ATM gene, whereby these patients are highly sensitive to DNA 
double strand break (DSB) inducers, such as ionizing irradiation (IR). Exposure of ATM 
knockout mice to IR resulted in reduced NF-κB DNA binding activity, and IKK kinase 
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activity when compare to wildtype mice. This data demonstrated in vivo, that ATM is 
required for IR induced IKK-NF-κB pathway (Li et al., 2001). NF-κB activation 
following UV-C radiation is IκB serine 32/36 phosphorylation independent, and take 
place through the activation of casein kinase II (CKII), instead of IKK, which 
phosphorylates IκBα in the C-terminal PEST domain, resulting in IκBα degradation 
(Kato et al., 2003; Lin et al., 1996; Tergaonkar et al., 2003). In summary, IR utilize IKK 
to phosphorylate serine 32 and 36 on IκBα, whereas UV-C utilize CKII instead of IKK, 
to phosphorylate IκBα in the C-terminal PEST domain, resulting in its degradation and 
activation of NF-κB. It is generally believed that the activation of NF-κB can lead to 
antiapoptotic cell signaling, providing an opportunity for cells to repair DNA damage. 
However, Campbell et al., showed that NF-κB is activated in response to UV-C radiation 
which led to the repression of antiapoptotic genes (Campbell et al., 2004b). Conflicting 
experimental data and views exist in the field in the investigation of the biological role of 
NF-κB activation in response to cell stress, and hence the role of NF-κB is not 
instantaneously clear. 
1.6 Regulation of  NF-κB transcriptional activation by post-translation modification 
1.6.1 Protein kinases as positive regulators 
The first phase of activation of NF-κB sets the stage for the second phase of NF-
κB activation. The second phase of NF-κB activation occurs in the nucleus, which 
involves NF-κB post-translational modification like phosphorylation and acetylation. The 
initial observation of phosphorylated p65 detected in TNFα-induced cells suggest that 
phosphorylation might play a role in the biology of NF-κB (Naumann and Scheidereit, 
1994). The inducible phosphorylation of NF-κB enhances NF-κB binding to DNA to 
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activate transcription, and the recruitment of transcriptional co-activator CBP/p300 that 
aid in transcription. Post-translational modification of NF-κB via phosphorylation 
therefore enhances the transactivation potential of NF-κB, and may render it 
constituitively active. Constituitive phosphorylation of NF-κB has been detected in 
cancer cells and many human disease like inflammation, has deregulated NF-κB activity. 
Thus, understanding the mechanism of the molecular switch of NF-κB phosphorylation 
and dephosphorylation will solve the puzzle of deregulated NF-κB in human diseases. 
The phosphorylation of NF-κB by various kinases occur in the cytoplasm or 
nucleus. Several phosphorylation sites on NF-κB have been identified. The 
phosphorylated residues on NF-κB are serine (S) 276, serine 311, serine 529, and serine 
536, whereby the key residues are serine 276 and serine 536 which influence NF-κB 
transcriptional activity (Figure 1.5). One example of such differential regulation takes 
place on serine 276, where mitogen and stress-activated protein kinase-1 (MSK1) 
phosphorylate serine 276 in the nucleus (Vermeulen et al., 2003). MSK1 phosphorylates 
p65 on S276 in vitro and in vivo. The effects of MSK1 on p65 phosphorylation is seen 
when L929 mouse fibroblast and human MDA-MB-231 breast cancer cells were treated 
with MSK1 inhibitor H89. Upon TNFα stimulation, the expression of NF-κB target gene 
IL-6 mRNA expression in these cells was reduced. Another one of such kinases that has 
an effect on  IL-6 mRNA expression is protein kinase C, zeta (PKC-zeta) that 
phophosphorylates p65 on serine 311 in response to TNFα (Duran et al., 2003). Mutation 
of serine 311 to alanine inhibits the prosurvival role of p65, and abrogates the interaction 
of p65 with its transcriptional co-activator CBP/p300 and RNA polymerase II to the IL-6 
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promoter. Both MSK1 and PKC kinase exert a positive effect on p65 phosphorylation 
and the transcription of p65 target gene IL-6.  
Protein kinase A (PKA) associates with IκBα and IκBβ in the NF-κB-IκB 
complexes in the cytoplasm (Zhong et al., 1997). Upon, LPS stimulation in pre-B cells, 
PKA is activated with correlation to IκB degradation. PKA then phosphorylates p65 on 
serine 276 in its close proximity, when IκB is degraded. It is believed that 
phosphorylation of NF-κB in the nucleus aid in the recruitment of transcriptional co-
activators for transcriptional activation. The reason to why NF-κB is phosphorylated in 
the cytoplasm and its significance remains to be unravelled. 
Another interesting kinase, CKII regulates NF-κB phosphorylation at two levels; 
firstly by phosphorylating IκBα to induce its degradation, and releasing NF-κB from its 
inhibitor, and secondly by phosphorylating p65 on serine 529 directly to increase NF-κB 
transcriptional activity (Bird et al., 1997; Wang et al., 2000). CKII kinase has been 
shown to be necessary for cell cycle progression and proliferation, because its protein 
levels are often observed to be elevated in proliferating non-neoplastic tissue and solid 
tumours (Vilk et al., 1999; Landesman-Bollag et al., 1998). Therefore, CKII may 
simultaneously co-operate with NF-κB to regulate cancer cell transformation, and cell 
proliferation. 
Another critical residue for phosphorylation on p65 is serine 536 which lies in the 
TAD domain. IKK kinase has dual function in positively regulating p65, firstly, to 
phosphorylate IκBα leading to its degradation and disassociation from p65, and secondly, 
to phosphorylate p65 directly on serine 536 to increase it transactivation potential, upon 
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TNFα induction of HeLa cells (Sakurai et al., 1999). Doxycycline inducible p53 
expression in Saos-2-tet-on p53 cells stimulates ribosomal S6 kinase 1 (RSK1), which in 
turn phosphorylates p65 on serine 536 in the nucleus (Bohuslav et al., 2004). The 
phosphorylation of p65 reduces p65 and newly synthesized IκBα interaction, hence 
reducing shuttling of p65-IκBα complex out of the nucleus, thus favouring nuclear 
retention of NF-κB to activate transcription. In addition to CKII kinase, RSK1 negatively 
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Figure 1.5 Multiple kinases phosphorylate p65 at various sites induced by distinct 
stimuli   
Four different phosphoacceptor sites, serine (S) 276, serine 311, serine 529 and serine 
536 have been identified in RELA. Phosphorylation of serine 276 is mediated by PKA 
and MSK1 which are activated by LPS and TNFα respectively. Serine 311 is 
phosphorylated by PKC which is activated by TNFα. Phosphorylation of serine 529 is 
mediated by CKII upon TNFα induction. Serine 536 is targeted for phosphorylation by 
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1.6.2 Protein phosphatases as negative regulators  
Many kinases have been shown to phosphorylate NF-κB, and the components of 
the NF-κB signaling pathway. The roles of phosphatases in NF-κB signaling pathway is 
not as well studied as the kinases. Li et al. elucidated the role of phosphatases in NF-κB 
signaling in a large scale RNAi screening (Li et al., 2006). They identified 13 NF-κB 
suppressing phosphatases out of 250 phosphatases genes, and confirmed the suppression 
of these phosphatases by RNAi knockdown, and measuring relative NF-κB activity in 
chemiluminescent transcription factor binding assay (CTFA). Through co-
immunoprecipitation (co-IP) experiments, the authors also showed that serine/threonine 
phosphatase, PP2A physically associates with, and dephosphorylates IKK , p65, and TNF 
receptor associated protein 2 (TRAF2). TRAF2 is an adaptor protein that lies in the NF-
κB signaling pathway, although the significance of TRAF2 phosphorylation is not well-
understood. 
The serine/threonine phosphatase family of protein comprises of four major 
phosphatase, PP1, PP2A, PP2B (Calcineurin) and PP2C. These protein phosphatases 
have been implicated in the negative regulation of the NF-κB signaling pathway. The 
serine/threonine family of protein phosphastase such as PP1, PP2A and PP2C negatively 
affect the NF-κB signaling pathway via the IKK complex. Through yeast two-hybrid 
screening, CUE domain-containing 2 (CUEDC2) protein was identified as an interacting 
partner of IKK1 and IKK2. CUEDC2 contains CUE domains which recognize mono and 
polyubiquitin. On top of its function in facilitating intramolecular monoubiquitination, 
and promote degradation of its interacting partner, CUEDC2 deactivates the IKK kinase, 
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and repressed the activation of NF-κB through recruiting protein phosphatase PP1 to the 
IKK complex (Li et al., 2008).  
The PP2A protein phosphatase has been shown to inhibit and dephosphorylate the 
IKK complex though its association with IKKγ (Fu et al., 2003). PP2A is responsible for 
the rapid deactivation of IKK, and this effect can be reversed by the interaction of PP2A 
with the transactivator/oncoprotein Tax of the human T-lymphotrophic virus type 1 
(HTLV-1), to result in constituitive IKK activity. In order for Tax to reverse the 
inhibition of PP2A to rapidly inactivate IKK, IKK-Tax-PP2A has to exist in a stable 
ternary complex, because PP2A-interaction-defective Tax mutants failed to activate NF-
κB. 
The PP2Cβ protein phosphatase has been reported to associate with the IKK 
complex through mass spectrometry studies (Prajapati et al., 2004). The association of 
PP2Cβ with the IKK complex led to the dephosphorylation of IKK2 in vivo and in vitro, 
and decreased its kinase activity upon TNFα stimulation. siRNA directed against PP2Cβ 
increases TNFα-induced IKK activity, and the overexpression of PP2Cβ decreases NF-
κB directed gene expression. The overexpression of PP2Cβ reduced the resynthesis of 
IκBα, a target gene of NF-κB, and affected the phosphorylation of IκBα and its 
degradation. These lines of evidences suggest that PP2Cβ negatively regulate NF-κB 
signaling pathway. 
The PP2B (Calcineurin) negatively regulate NF-κB signaling through the insulin-
like growth factor-1 (IGF-1) in astrocytes (Pons and Torres-Aleman, 2000). IGF-1 
protects neurons against a variety of brain pathologies (such as stroke, brain trauma and 
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multiple sclerosis) associated with glial overproduction of proinflammatory cytokines. 
The protective function of the IGF-1 signaling pathway is mediated through the induction 
and activation of PP2B when astrocytes are stimulated with IGF-1. Activation of PP2B 
by IGF-1 results in PP2B in dephosphorylating IκBα on serine 32, and the 
dephosphorylation of IκBα protects it from TNFα stimulated degradation, and hence 
prevented the translocation of p65 to the nucleus to activate transcription of 
proinflammatory cytokines. Therefore, the therapeutic effect of IGF-1 in the treatment of 
brain injury is through its inhibitory action on glial inflammatory reaction by negatively 
regulating NF-κB signaling pathway. 
1.7 Involvement of chromatin remodeling in transcriptional control of NF-κB target 
genes 
1.7.1 Chromatin remodeling- histone acetylation and histone deacetylation 
The packaging of DNA sequences into nucleosomes and higher-organized 
chromatin structures has been implicated in the regulation of gene transcription. Tightly 
packed chromatin block the accessibility of transcription factors, transcriptional co-
activators, and the replication machinery to binding DNA promoters, and therefore, 
inhibit gene transcription. Chromatin remodeling is a process whereby modifications take 
place on histone tails, resulting in the alteration in nucleosome structure, leading to 
increased accessibility of transcription factors and the basal transcription apparatus. 
Modification of histones requires the action of enzymes like ATP-dependent chromatin-
remodelling complexes like the SWI/SNF complex to changes the shape or position of 
specific nucleosomes (Flaus and Owen-Hughes, 2001).  
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Another group of enzymes histone acetyltransferases (HATs), histone 
deacetylases (HDACs), kinases and methyl transferases modify amino-terminal tails of 
histone proteins (H2A, H2B, H3 and H4), therefore influencing chromatin structures and 
transcriptional activity on DNA (Wu and Grunstein, 2000; Jenuwein and Allis, 2001). 
The opposing actions of histone acetylases (HATs) and histone deacetylases (HDACs) on 
the lysine residues of the histone tails influence transcription by modifying chromatin 
structure. HATs induce an open chromatin structure and transcriptional activation of 
genes while HDACs induce a closed chromatin structure and transcriptional repression 
(Figure 1.6).  
In order for NF-κB and the transcriptional machinery to gain access to NF-κB 
target genes promoter, chromatin remodeling is very much required. IKK1 subunit of the 
IKK kinase phosphorylates histone H3, and modulates chromatin accessibility at NF-κB 
responsive promoters. In IKK1 knockout MEF cells, decreased levels of phosphorylated 
H3 on serine10 and H3 acetylation has been observed (Anest et al., 2003; Yamamoto et 
al., 2003). These observations suggest that the phosphorylation of H3 on serine10 trigger 
the subsequent acetylation of histone H3 on lysine 14. p65 chromatin 
immunoprecipitation (CHIP) show that IKK1 is crucial for p65 binding to the 
intracellular adhesion molecule 1 (ICAM1) and monocyte chemotactic protein 1 (MCP1) 
promoter, but not the IκBα promoter. The mutation of the NLS on IKK1, which prevents 
its nuclear translocation, results in the complete loss of binding of p65 to the ICAM and 
MCP1 promoter. Therefore, the effect of IKK1 on κB sites is mostly promoter specific 
(Gloire et al., 2007).  
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High basal levels of histone H4 acetylation has been reported surrounding rapidly 
induced NF-κB target genes, IκBα, manganese superoxide dismutase (MnSOD) and 
macrophage inflammatory protein 2 (MIP2) (Saccani et al., 2001). In response to LPS 
stimulation, hyperacetylation of histone H3 and H4 within the regulatory regions of 
interleukin-8 (IL-8), interleukin-12 (IL-12), subunit p40 (IL-12/p40) and macrophage 
inflammatory protein 1-alpha (MIP1α) genes was also observed (Saccani et al., 2001; 
Zhong et al., 2002; Saccani and Natoli, 2002). On the contrary, the opposing action of 
histone deacetylation can result in decreased NF-κB transcription. Under unstimulated 
conditions, HDAC1 and p50 form a transcriptionally repressive complex, and the 
HDAC1-p50 complexes bind to κB sites of NF-κB target genes (Zhong et al., 2002). The 
recruitment of HDAC to NF-κB target gene promoter lead to histone deacetylation in the 
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Figure 1.6 Chromatin remodeling regulates transcriptional activity 
Post-translational modification on histone tails by methylation (ME), phosphorylation (P) 
or acetylation (Ac) can alter chromatin structure. Chromatin structure can be regulated by 
ATP-dependent chromatin remodellers, and the opposing action of histone 
acetyltransferases (HATs) or histone deacetylases (HDACs). DNA methylation and 
histone deacetylation induce a closed-chromatin structure and transcriptional repression, 
while histone acetylation and demethylation of DNA relaxes chromatin, allowing 
transcriptional activation. (Reproduced with permission from Nature Reviews Drug 
Discovery) (Johnstone, 2002) 
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1.7.2 p38 MAPK marks histones of  NF-κB target genes 
The response of cells to external stress signals and the transmission of the external 
signals to the inside of the cells are mediated by intracellular kinases. The mitogen 
activated protein kinase (MAPK), in particular, p38 MAPK, is one such serine/threonine 
kinase, that acts as a central point for different extracellular stimuli like heat, UV, 
inflammatory cytokines (IL-1, LPS, and TNF), and osmotic shock (Pearson et al., 2001). 
p38 MAPK function to regulate fundamental cellular processes involved in cell growth, 
cell cycle and inflammation. 
p38α was first isolated as a 38 kDa protein which was rapidly tyrosine 
phosphorylated in reponse to LPS stimulation (Han et al., 1994). Mammalian p38α was 
originally identified as the molecular target of the pyridinyl imidazole class of 
compounds, SB203580, known to inhibit the production of proinflammatory cytokines, 
TNF, IL-1, and LPS-induced human monocyte (Lee et al., 1994). There are four p38 
isoforms identified p38α, p38β, p38δ and p38γ, where the p38α and p38β are observed to 
be ubiquitously expressed (Jiang et al., 1996; Lechner et al., 1996; Jiang et al., 1997). 
p38 are activated by the dual phosphorylation of their Thr-Gly-Tyr motif by upstream 
mitogen-activated protein kinase kinase (MAPKK), mitogen-activated protein kinase 
kinase  3 (MKK3) and mitogen-activated protein kinase kinase 6 (MKK6) (Cohen., 1997; 
Kyriakis and Avruch, 2001), which in turn is phosphorylated by a serine/threonine kinase 
mitogen-activated protein kinase kinase kinase (MAPKKK) such as apoptosis signal-
regulating kinase 1 (ASK1) (Ichijo et al., 1997).  
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p38 MAPK has a substrate preference, for sites containing a serine or threonine 
followed by a proline residue (Songyang et al., 1996). Activated p38 MAPK in turn 
phosphorylates other physiological substrates like downstream kinases, MAP kinase-
activated protein kinase 2 (MAPKAPK2) and MSK1 (Cuenda and Rousseau, 2007). 
Inflammatory cytokine like TNFα activates p38 MAPK, which in turn phosphorylates 
and activates MSK1 to phosphorylate p65 on serine 276, and hence increasing p65 
transactivation potential. The effect of MSK1 is clearly demonstrated in RAW cells 
where the phosphorylation of p65 on serine 276 is reduced when MSK protein levels 
were knocked down (Olson et al., 2007). Similarly, the phosphorylation of p65 on serine 
529 and 536 occur through IKK and AKT activation in a p38MAPK fashion through 
inflammatory cytokine IL-1β stimulation (Madrid et al., 2001). Several transcription 
factors such as activating transcription factor-2 (ATF-2), p53 and CHOP, were also 
shown to be phosphorylated and subsequently activated by p38α (Cuenda and Rousseau, 
2007).  
p38 MAPK can also influence and coordinate the gene expression of different 
inflammatory cytokine, for example, interleukin-1, 6, 8 (IL-1, -6 -8), cyclooxygenase-2 
(COX2), MCP-1, and TNF (Shapiro and Dinarello, 1995; Beyaert et al., 1996; Hwang et 
al., 1997). In addition to phosphorylating downstream kinases and transcription factors, 
p38 MAPK can also influence chromatin remodeling through the phosphorylation of 
histones H3 on ser10. Saccani et. al. show that inflammatory stimuli like LPS can trigger 
p38 MAPK indirect phosphorylation of histone H3 on ser10, and by this mechanism, p38 
can selectively mark the promoters of various  inflammatory genes for example IL-8 and 
MCP1, for the recruitment of NF-κB to these gene promoter (Saccani et al., 2002). 
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1.7.3 p65 acetylation by p300 and CBP co-activators 
 Similar to histone proteins that can be acetylated and deacetylated, the p65 protein 
can undergo reversible acetylation and deacetylation. The significance of p65 
phosphorylation on serine 276, 311 and 536 is to recruit transcriptional co-activators 
CBP/p300 (acetyltransferases), to undergo reversible acetylation when cells are 
stimulated with TNFα (Zhong et al., 2002; Chen et al., 2005). The three main sites of 
acetylation identified on p65 are lysines (K) 218, 221, and 310 (Figure 1.2). p65 
acetylation on K221 impairs its interaction with its inhibitor, IκBα, and enhances DNA 
binding capability of NF-κB, while the acetylation on K310 does not affect its DNA 
binding capability nor IκBα interaction (Chen et al., 2002). Although K310 acetylation 
does not increase DNA binding nor inhibit IκBα interaction, it is definitely required for 
the full transcriptional activity of p65.  
 The activation of NF-κB and its subsequent translocation to the nucleus result in 
the transcription of its inhibitor and target gene IκBα. De novo synthesis of IκBα 
replenishes intracellular stores of this inhibitor that undergo degradation upon NF-κB 
activation in the cytoplasm. Newly synthesized IκBα in the nucleus exports NF-κB out of 
the nucleus into the cytoplasm, stopping NF-κB transcription in the nucleus, owing to the 
presence of NES on IκBα. The nuclear export of NF-κB is regulated by acetylation of 
NF-κB on lysine 218 and 221. Acetylation on lysine 218 and 221, renders weak 
interaction between p65 and IκBα, and hence hamper the nuclear export of p65. 
However, the deacetylation of lysine 218 and 221 by HDAC3 highly enhances p65 
interaction with IκBα, and thus favour nuclear export of p65 into the cytoplasm to 
terminate p65 transcription (Chen et al., 2001). Therefore, the dynamics of post-
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translational modification like acetylation, deacetylation and phosphorylation on p65 
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1.8 Objectives of study 
 Given the importance of how post-translation modification on NF-κB, and histone 
modifications such as histone deacetylation can affect the recruitment of NF-κB, and the 
transcriptional apparatus to gene promoters, in the first part of the thesis (chapter 3), I 
investigated the possibility of WIP1 in regulating the phosphorylation status and 
transcriptional activation of the p65 subunit of NF-κB, and in the second part of my thesis 
(chapter 4), I undertake the genome wide screening (microarray analysis) of genes that 
are associated to the NF-κB signaling pathway, genes that are activated or repressed by 
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2.1 Table 1: List of antibodies 





Actin Santa Cruz sc-1616 1:1000 Goat polyclonal 
IgG 
FLAG M2  Sigma-
Aldrich 





F7425 1:1000 Rabbit 
polyclonal IgG 






9241L 1:1000 Rabbit 
polyclonal 
NF-κB p65 (C20) Santa Cruz sc-372 1:1000 Rabbit 
polyclonal IgG 
NF-κB p65 (F6) Santa Cruz sc-8008 1:1000 Mouse 
monoclonal 
IgG1 











3039S 1:1000 Rabbit 
polyclonal 
p38 MAPK Santa Cruz Sc-535 1:1000 Rabbit 
polyclonal 




9211 1:1000 Rabbit 
polyclonal 
WIP1 (H-300) Santa Cruz Sc-20712 1:1000 Rabbit 
polyclonal 
IgG 
WIP1 BD lab  1:500 Mouse 
monoclonal 





610190 1:2500 Mouse 
monoclonal 




611324 1:250 Mouse 
monoclonal 
IgG1 









556321 1:1000 Mouse 
monoclonal 
IgM 
Lamin B Oncogene 
Research  
Products 





Abcam AB6721 1:5000 Goat polyclonal 
Mouse IgG-HRP Santa Cruz Sc-2031 1:2000 Goat polyclonal 
Goat IgG-HRP Santa Cruz Sc-2033 1:2000 Donkey 
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polyclonal 
p53 (DO-1) Santa Cruz Sc-126 1:2000 Mouse 
monoclonal 
IgG2a
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2.2 List of primers 
Gene (Human)                                     Sequence                                                   Tm (°C) 
1. β-actin (1) forward         5’- CATGTACGTTGCTATCCAGGC -3’                       55 
2. β-actin (1) reverse          5’- AGGTCCAGACGCAGGATGG-3’                            55 
3. β-actin (2) forward         5’- GCCAACCGCGAGAAGATGA-3’                            55 
4. β-actin (2) reverse          5’- CCA TCA CGA TGC CAG TGG TA-3’                     55 
5. Bid forward                    5’- TGAACCAGGAGTGAGTCGGA-3’                          55 
6. Bid reverse                     5’- AGCTCTCTGCGGAAGCTGTT-3’                            55 
7. BNIP3L forward            5’- GTGGAGCTACCCATGAACAG-3’                           55 
8. BNIP3L reverse             5’- TGCCCATCTTCTTGTGGCGA-3’                             55 
9. Clusterin forward           5’- TCTCAGACAATGAGCTCCAG-3’                           55 
10. Clusterin reverse          5’- CTTCTAGGTTGCTGAGCAGT-3’                            55 
11. IκBα forward                5’ - CGCACCTCCACTCCATCC -3’                               55 
12. IκBα reverse                 5’- AGCCATGGATAGAGGCTAAGTGTAG-3’            55 
13. IRAK1 forward            5’- TTCTCGGAGGAGCTCAAGATC- 3’                       55 
14. IRAK1 reverse             5’ - GTAGCCAGCAAAGTCCACAAT-3’                      55 
15. IL-2Rγ forward            5’- TTGAAGCCATCATTACCATTC -3’                        55 
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16. IL-2Rγ reverse                5’- ATAGTGGTCAGGAAGAAATCA-3’                     55 
17. IL-6 forward                   5’- TACATCCTCGACGGCATCTCA-3’                       55 
18. IL-6 reverse                    5’- CAGTGATGATTTTCACCAGGC-3’                       55 
19. IL-8 forward                   5 - GCCAACACAGAAATTATTGTAAAGCTT-3’      55 
20. IL-8 reverse                    5’- CCT CTGCACCCAGTTTTCCTT -3’                      55 
21. LTβR forward                5’- CTATGTCTCAGCTAAATGTAG-3’                       55 
22. LTβR reverse                 5’- GGTCTTCCGTTTGCTTGTGCA-3’                        55 
23. NF-κB1 forward            5’- TTATGTATGTGAAGGCCCATC -3’                      55 
24. NF-κB1 reverse             5’- AGATCCCATCCTCACAGTGTT -3’                      55 
25. Perp forward                  5’- ATTGGAGGTCTCCTTGCCTT -3’                         55 
26. Perp reverse                   5’- GTAGTTGAGGAGGCAGCAGA -3’                      55 
27. RAD9 forward               5’- ACGAGCTCTACCTGGAAC-3’                              55 
28. RAD9 reverse                5’- CTTCATCAGGATCTTACAGCG-3’                       55 
29. RAD21 forward             5’- TGCCTGAGGAAAATCGGGAA-3’                        55 
30. RAD21 reverse              5’- GATGTTCCCAACTTCTTCTCTC-3’                      55 
31. STAT3 forward             5’- TCCAACATCTGTCAGATGCC -3’                         55 
32. STAT3 reverse              5’- TTCTCTGCCAGTGTAGTCAG -3’                          55 
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33. TNFα forward               5’- TGGTATGAGCCCATCTATCTG-3’                        55 
34. TNFα reverse                5’- AGACTCGGCAAAGTCGAGATA-3’                      55 
35. WIP1 forward               5’- GGCTGTACTCGCTGGGAGTGAGCG-3’               55 
36. WIP1 reverse                5’- AGGCAACGGCTGAGACAGCGACCG -3’             55 
Gene (Mouse)                                      Sequence                                                      Tm (°C) 
1. β-actin forward                 5’- TTCGTTGCCGGTCCACA-3’                                 55 
2. β-actin reverse                  5’- ACCAGCGCAGCGATATCG-3’                             55 
3. ICAM forward                  5’- GTGAACTGTTCTTCCTCATGC-3’                       55 
4. ICAM reverse                   5’- CACTCTCCGGAAACGAATACA-3’                     55 
5. IκBα forward                    5’ - ACTTGGCAATCATCCACGAAG-3’                    55 
6. IκBα reverse                     5’- TCACAGCCAGCTTTCAGAAGT-3’                      55   
7. IL-6 forward                     5’- AAGAGACTTCCATCCAGTTGC-3’                      55 
8. IL-6 reverse                      5’- CTCCGACTTGTGAAGTGGTAT-3’                       55 
9. IRF forward                      5’- CTGGCTAGAGATGCAGATTAA-3’                     55 
10. IRF reverse                     5’- GACAGGCATCCTTGTTGATGT-3’                      55 
11. MCP1 forward                5’- CCACTCACCTGCTGCTACTCA-3’                      55 
12. MCP1 reverse                 5’- TGGTGATCCTCTTGTAGCTCT-3’                       55 
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13. MIP1α forward              5’- CGTTCCTCAACCCCCATC-3’                              55 
14. MIP1α reverse               5’- TGTCAGTTCATGACTTTGTCA-3’                      55 
15. TNFα forward                5’- ACAGAAAGCATGATCCGCG-3’                         55 
16. TNFα reverse                 5’- CTGGGCCATAGAACTGATG-3’                          55 
2.3 DNA/RNA methodology 
2.3.1 RNA isolation 
5 X 10 6 cells were treated with 10 ng/ml TNFα or 2 ng/ml IL-1 and cell culture medium 
was removed after treatment. Homogenisation: The cells were scraped off tissue culture 
plates using a cell scraper and resuspended in 1 ml TRIzol (Invitrogen, #15596-026). The 
homogenized sample was allowed to stand for 5 min at room temperature, to ensure 
disassociation of nucleoprotein complexes. Phase separation: 200 μl of chloroform was 
added and the tubes were mixed vigorously for 15 sec and incubated at room temperature 
for 3 min. The tubes were centrifuged at 13, 000 rpm for 15 min at 4°C. RNA 
Precipitation: The clear upper phase was collected and equal volume of 70% ethanol 
was added (to give a final ethanol concentration of 35%) to the collected sample drop by 
drop to avoid local precipitation. RNA wash: The sample was applied to RNAeasy 
column (Qiagen RNAeasy kit, #74106) and placed in a 2 ml collection tube. The tube 
was centrifuged 15 sec at 13, 000 rpm and the flow through was discarded. 700 μl of 
buffer RW1 was added, and the tube was centrifuged 15 sec at 13, 000 rpm. The flow 
through and collection tube was discarded. Transfer column to a clean 2 ml collection 
tube, add 500 μl buffer RPE, centrifuge 15 sec at 13, 000 rpm. Discard flow through. Add 
another 500 μl of buffer RPE, centrifuge 2 min at 13, 000 rpm and discard flow through. 
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Repeat centrifugation step at 13, 000 rpm for 1 min to completely dry column. Elute 
RNA by adding 30 μl of RNase/nuclease-free water directly to column membrane, 
centrifuge 1 min at 13, 000 rpm. 
2.3.2 First strand cDNA synthesis 
First strand cDNA synthesis was performed using SuperscriptTM First-Strand Synthesis 
System for RT-PCR (Invitrogen, #11904-018) according to manufacturers’ 
recommendations. The following components were prepared in RNase/nuclease-free 
eppendorf tubes for each reaction:  
Components     Volume 
1. Random hexamers    1 μl 
2. 10 mM dNTP mix    1 μl 
3. 1 ug total RNA    Variable 
4. RNase/nuclease-free water   Top up to a total volume of 11 μl 
The above mixture was heated to 65°C for 5 min and quickly chilled on ice for 1 min. 
The following was then added to each tube: 4 μl 5 X First-strand buffer, 1 μl 0.1M DTT, 
1 μl RNaseOUTTM recombinant ribonuclease inhibitor (40 units/μl) and 1 μl of 
SuperscriptTM II RT enzyme. The tubes were mixed and incubated at 25°C for 5 min 
followed by 50°C for 60 min. The reaction was terminated by heating at 70°C for 15 min. 
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2.3.3 Mini-preparation of plasmid DNA 
Small scale plasmid DNA preparation was carried out using QIAprep Miniprep Kit 
(Qiagen, #27104) according to manufacturer’s instructions. Briefly, a single colony from 
a freshly streaked selective plate was inoculated into 3-5 ml of LB containing ampicillin 
(100 μg/ml) in a 15 ml falcon tube. The bacterial culture was incubated for 12-16 hr at 
37°C with vigorous shaking (~300 rpm). Cells were harvested by centrifugation at 4, 000 
rpm in 4°C for 15 min. The pelleted cells were resuspended in 250 μl P1 buffer 
containing RNase A solution (final concentration of 0.1 mg/ml), followed by mixing 
gently in 250 μl of P2 lysis Buffer. The mixture was neutralized in 350 μl of N3 buffer 
and centrifuged at 13, 000 rpm for 10 min. The supernatant containing plasmid DNA was 
passed through the QIAprep spin column to allow DNA binding to the column and 
centrifuged at 13, 000 rpm for 60 sec. The flow through was discarded. The bound 
plasmid DNA was washed with 0.75 ml of PE buffer and centrifuged for 60 sec. The flow 
through was discarded and the QIAprep column was centrifuged for an additional 1 min 
to remove residual wash buffer. The QIAprep column was placed in a clean 1.5 ml 
microcentrifuge tube. The plasmid DNA was eluted with 50μl of EB buffer by 
centrifugation at 13, 000 rpm for 1 min. 
2.3.4 Maxi-preparation of plasmid DNA 
Large scale plasmid DNA preparation was carried out using QIAprep Maxiprep kit 
(Qiagen, #12163) according to manufacturer’s instructions. Briefly, the starter culture 
was inoculated in 250 ml ampicillin (100 μg/ml) containing LB at a dilution of 1/1000. 
The bacterial culture was incubated at 37°C for 12-16 hr with vigorous shaking (~300 
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rpm). Cells were harvested by centrifugation at 6, 000 rpm in 4°C for 15 min. The 
pelleted cells were resuspended in 10 ml P1 buffer containing RNase A solution (final 
concentration of 0.1 mg/ml), followed by mixing gently in 10 ml of P2 lysis buffer and 
allowed to stand at room temperature for 5 min. The cell lysate was neutralized with 10 
ml of chilled P3 buffer and mixed gently by inverting 4-6 times. The lysate was poured 
into the barrel of the QIAfilter maxi catridge and incubated at room temperature for 10 
min. Meanwhile, the QIAGEN-tip 500 was equilibrated by applying 10 ml QBT buffer 
and the tip was allowed to empty by gravity flow. The cap from the QIAfilter maxi 
catridge outlet nozzle was removed and the plunger was inserted into the catridge, and 
the lysate was filtered into the equilibrated QIAGEN-tip 500. After the lysate pass 
through completely, the tip containing bound DNA was washed twice with 30 ml of QC 
buffer. Plasmid DNA was eluted into polycarbonate centrifuge tubes with 15 ml of QF 
buffer. The eluted DNA was precipitated by adding 10.5 ml of room temperature 
isopropanol and centrifuged immediately at 15, 000 rpm in 4°C for 30 min. After the 
centrifugation step, the supernatant was carefully poured out and the DNA pellet was 
washed with 70% ethanol and centrifuged for a further 10 min at 15, 000 rpm. The 
supernatant was carefully poured out without disturbing the pellet. The pellet was 
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2.3.5 Sybr green real-time PCR 
Sybr green real-time PCR was carried out using BIORAD iQTM SYBR green supermix 
(BIORAD, #170-8882), according to manufacturer’s instructions. The real-time PCR 
reaction was set-up as follow: 
Components                                             Volume 
1. iQ SYBR green supermix                       12.5 μl 
2. Forward primer (2.5 μM)                          2.5 μl 
3. Reverse primer (2.5 μM)                           2.5 μl 
4. Water                                                         5.0 μl 
5. cDNA (5-25X diluted)                              2.5 μl 
The PCR reaction was set up as follow: 
Step                                                                  Temperature                      Time 
PCR cycling and detection (40 cycles):            
1.                                                                               95°C                          30 sec 
2.                                                                                95°C                         15 sec 
3.                                                                                55°C                         45 sec 
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Melt curve analysis: 
4.                                                                                95°C                              1 min 
5.                                                                                55°C+                             1 min 
6.                                                                                55°C*                            10 sec 
+ Approximately 5°C below the Tm (melting temperature) of primers 
* The reaction is repeated at step 6 for 81 cycles, increasing each by 0.5°C each cycle 
2.3.6 Quantitect sybr green real-time PCR 
Sybr green real-time PCR was carried out using QuantiTectR SYBRR Green PCR 
(QIAGEN, #204143), according to manufacturer’s instructions. The real-time PCR 
reaction was set up as follow: 
Components                                              Volume 
1. Sybr Green                                              12.5 μl 
2. Forward primer                                       0.3 μM 
3. Reverse primer                                        0.3 μM 
4. cDNA                                                          1 μl 
5. DEPC water                                           Top up to a total volume of 25 μl 
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The PCR reaction was set up as follow: 
Step                                                Temperature                                 Time  
PCR detection and cycling step (35 cycles):   
1. PCR initial activation step            95°C                                           15 min 
2. Denaturation                                 94°C                                            15 sec 
3. Annealing                                     50-60°C                                       30 sec 
4. Extension                                      72°C                                            30 sec 
2.3.7 Agarose gel electrophoresis 
6 X DNA loading dye (0.1% bromophenol blue, 40% sucrose, 240 mM Tris-HCL pH7.4, 
60 mM EDTA-Na pH8.0) was added to plasmid DNA/PCR products to a final 
concentration of 1 X. 1-2% (W/V) agarose gel (Invitrogen, 15510-027) was prepared by 
dissolving agarose gel in 1X TAE buffer (0.04 M Tris-acetate, 0.001 M EDTA) through 
heating in a microwave oven. 0.5 μg/ml ethidium bromide was added to the agarose gel 
cooled down to room temperature and the gel was poured into a gel cast mould and 
allowed to solidify. The solidified agarose gel was ran in a electrophoresis tank with 1X 
TAE buffer. DNA samples and 1 μg of 2 log DNA ladder (New England Biolabs, 
N3200S) were loaded into the gel wells and the gel was ran at 100 volts.  The separated 
DNA bands were visualized using UV trans-illuminator (Syngene Bio Imaging). 
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2.3.8 DNA sequencing 
The sequencing of DNA was performed by PCR. 500 ng of plasmid and 3.2 ρmol of 
primer and 8 μl of big dye mix (obtained from core sequencing facility) were mixed to a 
total volume 20 μl. The cycling conditions for the PCR sequencing is as follow: 
Step                                                    Temperature                                     Time  
1. Initial denaturation                             96°C                                           2 min 
2. Denaturation                                       96°C                                          30 sec 
3. Annealing                                           50°C                                          30 sec 
4. Extension                                            60°C                                           4 min 
The reaction was repeated from step 1 to 4 for 25 cycles. After the PCR reaction is 
completed, the DNA was precipitated with 80 μl of 100% ethanol and allowed to stand at 
room temperature for 15 min and then centrifuged at 13, 000 rpm for 20 min. The 
supernatant was discarded and the DNA pellet was washed with 150 μl of 70% ethanol 
and centrifuged at 13, 000 rpm for 5 min. The ethanol was discarded and the DNA pellet 
was left to air dry. The DNA was resolved and read using Perkin-Elmer ABI prism 377 
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2.3.9 One-step RT-PCR 
One-step RT-PCR was carried out using one-step RT-PCR kit (QIAGEN, #210212), 
according to manufacturer’s instructions. The one-step RT-PCR reaction was set up as 
follow: 
Components                                                                     1X 
1. One step RT-PCR buffer (5 X)                                     10 μl 
2. dNTP                                                                               2 μl 
3. Forward primer (25 ρmol/μl)                                          2 μl 
4. Reverse primer (25 ρmol/μl)                                           2 μl 
5. One step PCR enzyme mix                                             2 μl 
6. Template RNA (2 ug)                                                Variable 
7. DEPC water                                                              Top up to total volume of 50 μl 
The PCR reaction was set up as follow: 
Step:                                                              Temperature                             Time 
1.  Reverse transcription                                    50°C                                    35 min 
2. Initial PCR activation step                             95°C                                    15 min 
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Three step cycling 
3. Denaturation                                                 94°C                                     15 sec 
4. Annealing+                                                                       50°C-68°C                           30 sec 
5. Extension*                                                     72°C                                      1 min 
6. Final Extension                                             72°C                                    10 min 
+ Approximately 5°C below the Tm (melting temperature) of primers 
* The reaction is repeated from step 2 to 4 for 25-40 cycles 
2.4 Protein methodology 
2.4.1 Protein concentration determination by Bradford assay 
Protein standards of 5 mg/ml, 2.5 mg/ml, 1.25 mg/ml, 0.625 mg/ml, 0.3125 mg/ml and 0 
mg/ml were prepared from 10 mg/ml BSA (New England Biolabs, B9001S). 5μl of the 
protein standards were added to 995 μl of 20% (V/V) Bio-rad protein assay reagent (Bio-
rad laboratories, #500-0006), and allowed to stand at room temperature for 5 min. The 
protein standards were transferred to plastic cuvettes and absorbance was read at 595 nM 
in a photospectrometer (GeneQuant, Amersham Biosciences). A standard curve was 
generated with the absorbance reading against protein concentration. Protein samples 
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2.4.2 Protein isolation from mouse tissue 
5-10 mg of mouse tissue were cut into small pieces and resuspended in PBS containing 
protease inhibitors (Roche, #11697498001), 200 mM sodium vanadate and 10 mM 
sodium fluoride. The sample was subjected to sonication (Sonics Vibracell) for 15 sec 
(repeated 3 X) at 30% amplitude, with 10 sec to cool in between. The sample was 
centrifuged at 13, 000 rpm for 20 min, and the supernatant containing the protein was 
transferred to a clean eppendorf tube. 
2.4.3 Western blotting 
Cells were lyzed on ice in RIPA lysis buffer (150 mM NaCl, 1% NP40, 0.5% Sodium 
deoxycholate, 0.1% SDS, 50 mM Tris pH 8.0) containing protease inhibitor (Roche, 
#11697498001). The cell pellet was centrifuged at 13, 000 rpm for 10 min at 4°C, the 
supernatant containing protein was transferred to a clean eppendorf tube and the protein 
concentration was determined (see 2.4.1). 2 X Protein loading buffer (100 mM Tris-HCl 
pH 6.8, 4% (W/V) SDS, 0.2% (W/V) bromophenol blue, 20% (V/V) glycerol and 200 
mM DTT) was added to the protein sample to a concentration of 1 X, followed by protein 
denaturation by boiling at 95°C for 5 min before subjecting to SDS-PAGE gels 
electrophoresis at 150 volts. After protein separation, the protein was transferred onto 
immunoblot PVDF membrane (Bio-rad laboratories, #162-0177) for 1 hr at 100 volts. 
Membranes were blocked with 5% (W/V) non-fat milk or 3% (W/V) bovine serum 
albumin in PBST or TBST for 1 hr at room temperature on a shaker. After the blocking 
step, primary antibody was added to the blocking solution at working concentration and 
left to incubate overnight at 4°C. Membranes were washed in PBST (1.5 mM Potassium 
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phosphate monobasic, 2.68 mM potassium chloride, 8 mM sodium phosphate dibasic, 
and 0.1% tween-20) or TBST (20 mM Tris base, 138 mM NaCl and 0.1% tween-20), and 
the appropriate species of horseradish peroxidase (HRP)-linked secondary antibody was 
added to the membrane in the appropriate blocking agent and incubated for 1 hr at room 
temperature. The membranes were washed in PBST or TBST followed by detection by 
ECL western blotting detection reagent (Amersham Biosciences, #RPN2106) and X-ray 
film (Amersham Biosciences, #28906844).  
2.4.4 Immunoprecipitation 
Adherent cells were washed with ice cold PBS and the cells were lyzed in IP lysis buffer 
(0.5% NP40 alternative, 170 mM NaCl, 50 mM Tris pH 8.0, 50 mM NaF), and harvested 
by scraping off the cells. The cell lysates were kept on ice for 20 min followed by 
centrifugation at 13, 000 rpm for 10 min at 4°C. The supernatant were transferred to a 
clean tube and the protein concentration was determined (see 2.4.1). 1 mg of protein cell 
lysates were pre-cleared with 200 μl of pre-washed 10% (W/V) protein G agarose beads 
slurry (Amersham Biosciences, #17-0618-02) and incubated at 4°C for 1 hr. The beads 
were removed by centrifugation at 13, 000 rpm in 4°C for 30 sec. 1 μg of antibody and 
200 μl of beads slurry was added to the pre-cleared lysate and the sample was tumbled 
overnight at 4°C on a tube rotator (Barnstead thermolyne). The beads were collected by 
centrifugation at 13, 000 rpm in 4°C and washed 4 X with 1 ml IP wash buffer (100 mM 
NaCl, 200 mM Tris pH 8.0, 0.5% NP40). After the final wash, the beads were 
resuspended in 2 X loading buffer (see 2.4.3) and the protein was denatured by boiling at 
95°C for 5 min before loading and resolving on a SDS-PAGE gel. 
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2.4.5 Transient transfection methods 
2.4.5.1 Lipofectamine 2000 transfection for plasmid DNA 
HeLa cells with a 70% confluency were transiently transfected with lipofectamineTM 
2000 (Invitrogen, #11668-019), according to manufacturer’s instructions. Briefly, 
adherent cells were washed with PBS and the media was replaced with DMEM 
containing 1% FCS without antibiotics before transfection. The complexes are prepared 
as follow: 
Components                                      6 well                             10cm dish
Lipofectamine 2000                              2 μl                                     12 μl 
OptiMEM                                          150 μl                                   900 μl 
Plasmid                                                 1 μg                                      6 μg 
OptiMEM                                          150 μl                                   900 μl 
Plating media                                     700 μl                                 4200 μl 
(1% FCS, no antibiotics) 
Diluted lipofectamine and diluted DNA were mixed together and incubated at room 
temperature for 20 min. After 20 min incubation, the complexes were added to the cells 
and mixed gently. 4-6 hr later, replace media with DMEM containing 10% FCS and 
antibiotics. Incubate the cells at 37°C in a CO2 incubator for 18-48 hr prior to testing of 
transgene expression. 
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2.4.5.2 Lipofectamine 2000 transfection for siRNA oligonucleotides 
The procedure for the transfection is the same as mentioned in 2.4.5.1 except the 
complexes were prepared as follow:  
Components                                                6-well (1X) 
Lipofectamine 2000                                            5 μl 
OptiMem                                                         245 μl 
Components                                                6-well (1X) 
siRNA oligonucleotide (10 μM)                       20 μl 
OptiMem                                                         230 μl 
The target sequences of the pre-designed siRNA oligos from Ambion are shown 
below: 
Oligo ID no.      Sense sequence         
1. 2566             5’-GGAAAUGUCCAAUCAGGGAtt-3’ 
2. 2658            5’ -GGAAAUUCAAAAUGCUGUCtt-3’ 
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Oligo ID no.      Antisense sequence     
1. 2566              5’ -UCCCUGAUUGGACAUUUCCtg-3’ 
2. 2658              5’ -GACAGCAUUUUGAAUUUCCtt-3’ 
3. 2745              5’-AUAAAUUUAGGGUUCUUCCtg-3’ 
The negative control 4611, 4613 and 4615 comprised of a 19 bp scrambled sequence with 
3’ dT overhangs and no significant homology to any known gene sequences from mouse, 
rat, or human. 
2.4.6 Nuclear extraction  
Nuclear extraction of cells was performed using a nuclear extraction kit (Panomics, 
#AY2002). Briefly, the cells are grown to near confluency (1X107 cells per 10 cm tissue 
culture plate) before harvesting. The plate was washed with 10 ml of ice cold PBS twice. 
1 ml of Buffer A mix was added to each plate, and the plates were left on ice in an ice 
bucket, and the ice bucket was left to shake at 150 rpm on a shaking platform for 10 min. 
After shaking, the cells were scraped off the plate with a plastic cell scraper and mixed by 
pipetting up and down several times to disrupt cell clumps in an eppendorf tube. The 
tubes were centrifuged at 13, 000 rpm for 5 min at 4°C. The supernant (cytosolic 
fraction) was transferred into a clean eppendorf tube. The cell pellet was resuspended in 
150 μl Buffer B mix and vortexed for 10 sec. The tubes were left to lay flat in an ice 
bucket and left to shake on a shaking platform at 200 rpm for 2 hr. After shaking, the 
tubes were centrifuged at 13, 000 rpm for 5 min at 4°C. The supernatant (nuclear extract) 
was transferred to a clean eppendorf tube. The protein concentration of the cytosolic and 
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nuclear extract was determined (see 2.4.1) before subjecting to analysis on a SDS-PAGE 
gel. 
Buffer A mix                                         Volume 
1) 1 X Buffer A*                                        1 ml 
2) 100 mM DTT                                       10 μl 
3) Protease inhibitor cocktail                   10 μl 
4) 10% IGEPAL                                      40 μl 
* Prepare a 1 X diluted working solution from a 10 X Buffer A Stock (100 mM HEPES         
   pH 7.9, 100 mM KCl, 100 mM EDTA). 
Buffer B mix                                            Volume 
1) 1 X Buffer B+                                         147 μl 
2) Protease inhibitor cocktail                      1.5 μl 
3) 100 mM DTT                                          1.5 μl 
+ Prepare a 1 X diluted working solution from a 5 X Buffer B Stock (100 mM HEPES pH  
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2.5 Mammalian cell culture and assays 
2.5.1 Cell culture and drug treatments 
Mammalian cell lines, Saos-2 cells expressing a tet-on inducible WIP1 phosphatase, 
HeLa control, HeLa WIP1siRNA, transformed WT and transformed WIP1 knockout 
MEF (All the above cell lines were kind gifts from BD lab). HeLa, HCT116, Saos-2 and 
MEF cells were cultured in DMEM, and U937 and Jurkat cells were cultured in RPMI 
1640 supplemented with 10% heat inactivated FCS, 100 units/ml penicillin, 100 μg/ml 
streptomycin in a humidified atmosphere at 37°C and 5% CO2 incubator. TNFα and IL-1 
was purchased from Calbiochem (catalogue no. 654205 and 407611) and reconstituted in 
PBS containing BSA to a stock concentration of 10 μg/ml and 2 μg/ml respectively. 
Trichostatin A (TSA) was purchased from Sigma-Alrich (catalogue no. T8552) and 
reconstituted in DMSO to a stock concentration of 1 mM. p38 MAPK inhibitor 
SB202190 was purchased from Sigma-Aldrich (catalogue no. S7067) and reconstituted to 
a stock concentration of 15 mM. Okadaic acid was purchased from Millipore (catalogue 
no. 19-130) and reconstituted to a stock concentration of 100 μM. Doxycycline 
hydrochloride was purchased from Sigma-Aldrich (catalogue no. 44577) and 
reconstituted to a stock concentration of 5 mg/ml. 
2.5.2 Apoptosis assay- PI staining 
Apoptosis was measured using fluorescence-activated cell sorting (FACS) analysis of 
cells in sub-G1 phase. Cells were harvested and fixed in 70% ethanol. The fixed cells 
were then stained with 50 μg/ml propidium iodide (BD Pharmingen, #556463) after 
treatment with RNase (100 μg/ml). The stained cells were analyzed for DNA content by 
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FACS Calibur (BD Biosciences) and the cell cycle fractions were quantified with 
Cellquest software (BD Biosciences). 
2.5.3 Cell proliferation assay-Wst-1 
To measure cell survival by Wst-1 (Roche, # 11644807001), cells were plated at 1-2X106 
cells per well in a 96 well plate and treated with 1 μM TSA. Wst-1 was added to the cell 
culture medium at a 1:10 dilution and incubated at 37°C for 1 hr or until the colour of the 
medium turned red (incubation time can vary according to the cell number in the culture). 
The absorbance was measured at a wavelength of 420 nM.  
2.5.4 Sytox-hoechst cell staining 
To determine the apoptosis of cells, cells were plated at 1-2X106 cells per well in a 96 
well plate and treated with 1 μM TSA. The cell cultures were stained with a mixture of 
the membrane permeable DNA dye Hoechst-33342 (Invitrogen, #H3570) at a final 
concentration of 500 ng/ml and the membrane impermeable DNA dye SYTOX 
(Invitrogen, #S7020) at a final concentration of 500 nM. Apoptotic cells were 
photographed using a Zeiss epifluorescence microscope with an attached Nikon Coolpix 
digital camera. 
2.5.5 Luciferase reporter gene assay  
HeLa cells were transfected with lipofectamine 2000 (see 2.4.5.1). 0.5 μg of NF-κB 
luciferase reporter plasmid, 0.2 μg Renilla plasmid and 0-2 μg of WIP1 plasmid was 
transfected into each well in a 6 well plate. The total amount of transfected DNA in each 
well was kept constant by adding empty vector pGL3 basic vector. To correct for 
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variation in transfection efficiency, reporter firefly luciferase activity was normalized to 
Renilla luciferase activity which was measured using the dual luciferase reporter assay 
system kit (Promega, #E1980), according to manufacturer’s instructions. Briefly, the cells 
were lysed in passive lysis buffer (PLB) with gently shaking on a rocking platform for 15 
min at room temperature. Cell lysates were centrifuged at 13, 000 rpm for 30 sec to clear 
the cell debris. The supernatant was transferred to a clean eppendorf tube. 20 μl of each 
cell lysate sample (in triplicate) was dispense into each well of a 96 well plate. 100 μl of 
luciferase assay reagent (LARII) was added to each sample and the activity of firefly 
luciferase was quantified using a luminometer (Berthold technologies). Subsequently, 
100 μl of Stop and Glo reagent which simultaneously quenches firefly luciferase activity 
and activates Renilla luciferase was added to the sample. Similarly, the activity of Renilla 
was quantified in a luminometer.  
2.5.6 In vitro phosphatase assay 
Activated, phosphorylated p65 and p65 S536A mutant protein was immunoprecipitated 
from whole cell lysates as described in 2.4.4. After the last wash, the beads were 
centrifuged at 13, 000 rpm for 30 sec. The beads from each sample were resuspended in 
160 μl of phosphatase buffer (50 mM Tris-HCl pH7.5, 0.1 mM EGTA, 0.02% 2-
mercaptoethanol, 40 mM NaCl, 30 mM MgCl2). 160 μl of beads from each sample were 
split into two separate tubes (80 μl each) with one tube containing 1 μg of recombinant 
WIP1 phosphatase protein (a kind gift from BD lab), while the other tube contain mock 
buffer (50 μl 2 X phosphatase buffer + 50 μl 100% glycerol). The tubes were incubated in 
a 30°C heat block for 1 hr and the phosphatase reaction was terminated by addition of 2 
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X SDS loading buffer. Samples were resolved on a SDS-PAGE gel and subjected to 
immunoblot analysis using anti-phospho p65 antibody. 
2.6 Microarray hybridization and data analysis 
2.6.1 Sample (probe) labeling by reverse transcription  
Step1: Total RNA isolated from TSA-treated cells was prepared as a RNA mix as follow: 
Components                                       Volume 
1. Sample RNA (Cy5)                       40 μg 
2. Oligo dT (0.5 mg/ml)                       2 μl 
3. RNase-free water                           variable 
Total volume                                      19 μl 
Components                                        Volume 
1. UHR RNA (reference, Cy3) +         40 μg 
2. Oligo dT (0.5 mg/ml)                         2 μl 
3. RNase-free water                           variable 
Total volume                                        19 μl 
+ Universal human reference RNA (UHR) was obtained from Stratagene, #740000 
Step 2: Heat to 65°C for 10 min and cool on ice for 2 min. 
Step 3: Prepare RT reaction mix as follow: 
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Components                                          Volume 
1. 5 X 1st strand buffer                               8 μl 
2. 20 X low T dNTP mix                           2 μl 
(10 mM A, C & GTP, 4 mM dTTP) 
3. Cy5 or Cy3 dUTP (1 mM)                     4 μl 
4. 0.1 M DTT                                             4 μl 
5. RNasin (30 U/μl)                                   1 μl 
6. Superscript II (200 U/μl)                       2 μl 
Total volume                                           21 μl 
Step 4: Add RNA mix to RT reaction mix to pre-mix to heat block pre-set to 42°C for 1.5 
hr. 
Step 5: After heating, put reactions on ice. 
Step 6: Add 5 μl of 0.5 M EDTA and mix well. 
Step 7: Add 10 μl of 1 M NaOH (fresh), mix well and centrifuge at 13, 000 rpm for 10      
sec. 
Step 8: Put on heat block pre-set to 65°C for 30 min, after heating, cool to room 
temperature for 5 min. 
Step 9: Add 25 μl of 1 M Tris-HCl (pH 7.5). 
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2.6.2 Probe purification 
Step1: Label on white area of column, push column into the collection tube. 
Step 2: Wash Microcon YM-30 centrifugal filter unit (Millipore, #42410) with 500 μl of 
water, spin 13, 000 rpm for 10 min, leave approximately 30 μl of water in the column. 
Step 3: Add 400 μl of water to RT reaction tube (Cy3 labeled) and load onto pre-washed 
column, spin 13, 000 rpm for 7 min. 
Step 4: Add 450 μl of water and centrifuge again (repeat wash until the eluate colour is 
not so intense. 
Step 5: Change a clean tube, invert Cy3 to a clean tube and spin at 13, 000 rpm for 1 min. 
Step 6: Combine Cy3 to Cy5 column (pre-washed), mix well and carefully not to break 
membrane. Load 400 μl of water and spin 13, 000 rpm for 10 min. After centrifugation, 
make sure volume left in the column is approximately 10 μl.  
Step 7: To elute sample, invert column into a clean tube, centrifuge 13, 000 rpm for 1 
min. 
Step 8: Check the volume of eluate, bring the volume to 18 μl using water. Add 4 μl of 
herring sperm DNA (Sigma-Aldrich, #D3159), heat 100°C for 2 min, add 22 μl of DIG 
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2.6.3 Microarray hybridization 
2.6.3.1 Pre-hybridization 
Step 1: Add 44 μl of DIG Easy Hyb hybridization buffer (Roche, #1603558) to printed 
oligonucleotide microarray slide (Genome Institute of Singapore) and cover with slip. 
Place the slide in the hybridization chamber. Add approximately 30 μl of water to the 
sides of the hybridization chamber to keep chamber hydrated. Tighten chamber 
(diagonally) before immersing into a 42°C water bath for at least 1 hr. 
Step 2: After incubation, place slides into distilled water gently for 2 min, allowing slip to 
come off naturally to avoid scratching the surface of the printed oligonucleotide slide. 
Step 3: Dunk the slides into water for 2 min. 
Step 4: Dunk the slides into isopropanol for 2 min. 
Step 5: Spin the slides at 100 g for 4 min to dry slide. 
2.6.3.2 Hybridization 
Step 1: Add 44 μl of labeled cDNA to the printed slide and cover with a cover slip. Place 
the slide in the hybridization chamber. Add approximately 30 μl of water to the sides of 
the hybridization chamber to keep the chamber hydrated. Tighten the chamber diagonally 
before immersing into a 42°C water bath overnight. 
Step 2: After hybridization overnight, place the slides into distilled water for 2 min to 
remove cover slip gently. 
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Step 3: Dunk the slides into washing buffer (SSC) sequentially from a higher 
concentration to a lower concentration- 2 X SSC, 1 X SSC, 0.2 X SSC, 0.05 X SSC for 2 
min at each concentration. 
Step 4: Spin the oligonucleotide slides at 100 g for 4 min to dry slide and scan for image 
analysis using Genepix 3.0 software (Axon Instruments, Inc., Foster City, CA).  
2.6.4 Data analysis 
The microarray image processing, analysis and normalization was performed using 
Genepix 3.0 software. Briefly, a normalization factor was calculated to rescale each gene 
in the array so that the median fluorescence ratio of all spots was 1.0. The data were then 
filtered so that only spots with intensities two times greater than the background were 
used in the analysis. The log ratio for each time point was then normalized for each gene 
to that of the untreated cells (time 0) to obtain the relative expression pattern. The genes 
that showed substantial differences after TSA treatment were selected based on 2-fold 
change of expression value for at least two time points across all experiment conditions. 
A total of 723 of 19, 000 genes met the criteria and were further analyzed using 
clustering and display program (rana.stanford.edu/software) developed by Eisen et al. 
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3.1 Introduction 
p38 MAPK can influence the expression of proinflammatory cytokines through 
chromatin remodeling and positively affecting the transactivation potential of NF-κB 
indirectly through phosphorylating its downstream substrate kinase such as MSK1 (Olson 
et al., 2007). Inhibiting p38 MAPK activity by mutation or addition of p38 MAPK 
inhibitor in LPS stimulated macrophages decreased TNFα cytokine mRNA expression, 
and thus has a negative effect in inflammation (Campbell et al., 2004a). The Wildtype 
p53 induced phosphatase 1 (WIP1) is a negative regulator of p38 MAPK and function to 
inactivate p38 MAPK through the dephosphorylation of threonine 180 and tyrosine 182 
on active p38 MAPK (Takekawa et al., 2000). Since inactivating p38 MAPK can 
negatively affect inflammation, it is possible that WIP1 phosphatase may exert a negative 
effect on inflammation through p38 MAPK. 
The WIP1 phosphatase is initially discovered in WMN burkitt’s lymphoma cells, 
and is induced by ionizing radiation (IR) and UV in a p53 dependent manner (Fiscella et 
al., 1997). WIP1 belongs to the serine/threonine PP2C family of phosphatases, and like 
many PP2C phosphatases, is magnesium dependent for its activation, and insensitive to 
inhibition by okadaic acid. WIP1 phosphatase recognizes and dephosphorylates 
phosphoserine and phosphothreonine in the p (S/T) Q motif, and in addition, acidic, 
hydrophobic, or aromatic amino acids surrounding the p (S/T) Q sequence have a positive 
influence, while basic amino acids have a negative influence on substrate 
dephosphorylation (Yamaguchi et al., 2007). The protein targets of WIP1 phosphatase 
include tumour suppressor p53 which mediates apoptosis, and cell cycle regulation 
checkpoint proteins like ATM (Sheeram et al., 2006), CHK1(Lu et al., 2005) and CHK2 
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(Fujimoto et al., 2006), which are activated upon DNA damage (Figure 3.1). It was 
proposed that WIP1 functions to reverse DNA damage response by dephosphorylating 
the above proteins, restoring the cells to its homeostatic state, after cells have adequately 
repair its DNA.  
 The role of WIP1 is controversial, and has also been proposed to be an oncogene. 
WIP1 is often observed to be amplified and overexpressed in human tumours. WIP1 
dephosphorylate p53 on serine 15, although there is no physical interaction observed by 
co-immunoprecipitation (Lu et al., 2005). WIP1 may therefore inactivate p53 whereby 
p53 is still intact in these tumour cells. WIP1 is proposed to create a negative loop for 
p53 by dephosphorylating p38 MAPK (Takekawa et al., 2000), an upstream kinase of 
p53, and its interacting partner MDM2 which promotes its degradation (Lu et al., 2007). 
The p38 MAPK physically associate with p53 and phosphorylate p53 on serine 33 and 
serine 46 in response to UV radiation to stimulate p53 mediated transcription, cell cycle 
and apoptosis. WIP1 by inactivating p38 MAPK disrupt p53 mediated apoptosis. In 
addition, WIP1 also dephosphorylates MDM2, and inhibits its autoubiquitination, thus 
stabilizing MDM2 protein levels. Stabilized MDM2 protein has increased affinity for 
p53, bind p53 and promote its ubiquitination and degradation, thus disrupting the 
proapoptotic function of p53. The WIP1 phosphatase thus acts as a gatekeeper in the p53-
MDM2 autoregulatory loop. 
Increased inflammation has been observed in the organs of WIP1 deficient mice 
as compared to their wildtype counterparts (Choi et al., 2002). It remains unclear if WIP1 
phosphatase can regulate the activity of NF-κB through direct dephosphorylation of NF-
κB, or any of the signaling component of the NF-κB pathway, or indirectly through 
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dephosphorylation of p38 MAPK, therefore resulting in the increased inflammation of 
organs observed in the WIP1 deficient mice. In this section, we investigate if WIP1 
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Figure 3.1 WIP1 in cell cycle regulation and apoptosis 
WIP1 plays a role in apoptosis by dephosphorylating p53 on serine 15, p38MAPK on 
threonine 180 and tyrosine 182, and MDM2 on serine 395. WIP1 also return cells to its 
homeostatic state by dephosphorylating cell cycle regulation checkpoint proteins ATM 
on serine 1981, CHK1 on serine 345, and CHK2 on serine 68.    
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3.2 Mice lacking WIP1 show increased activation of NF-κB and phosphorylation of  
       p65 on serine 536      
 
NF-κB is a transcription factor and is directly involved in the transcription of 
inflammatory cytokines such as TNFα and MIP1α. The role of WIP1 in regulating NF-κB 
transcriptional activation was investigated via measuring mRNA transcript of its target 
genes IκBα, TNFα and MIP1α by real-time PCR. Because MEF from WIP1 knockout 
mice do not survive long in culture, they were transformed with two oncogenes, E1A and 
Ras to immortalize the MEF so as to prolong their life span in culture. As shown in 
Figure 3.2, the basal mRNA level of MIP1α, TNFα and IκBα was approximately 10-fold, 
35-fold, and 2-fold higher respectively in unstimulated WIP1 deficient transformed MEF 
as compared to wildtype transformed MEF (Figure 3.2A). 
As increased inflammation was observed in the organs of WIP1 deficient mice 
(Choi et al., 2002), we investigated the activation of NF-κB through its phosphorylation 
status because NF-κB phosphorylation has been correlated with its enhanced 
transcriptional activity. We analyzed a panel of mouse organs, the brains, heart, spleen, 
thymus (data not shown), kidneys, and lungs of wildtype and WIP1 deficient mice and 
found that the phosphorylation of p65 on serine 536 was higher in the kidneys of WIP1 
deficient mice (Figure 3.2B) and approximately 2-fold higher as shown by densitometric 
quantification of the western blot results (Figure 3.2C). Although the levels of 
phosphorylated p65 is increased in the kidney of WIP1 deficient mice, the levels of total 
p65 is shown to be consistent and not affected by the phosphorylation levels of p65 on 
serine 536 (Chew et al., 2009). 
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    Figure 3.2 
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Figure 3.2 Mice lacking WIP1 show increased activation of NF-κB and    
                   phosphorylation of  p65 on serine 536.        
A) Sybr green real-time PCR of NF-κB target genes IκBα, MIP1α and TNFα in 
unstimulated wildtype and WIP1 deficient MEF using gene-specific primers. Data is the 
mean standard deviation (S.D.) of two samples in one experiment representative of three 
independent experiments. B) Western blot detection of phosphorylated p65 on serine 536 
using a specific phosphos-antibody in WIP1 wildtype and WIP1 deficient mouse tissues. 
C) Phosphorylated p65 in the kidney of WIP1 deficient mice was quantitated using a 
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3.3 Overexpression of WIP1 reduces p65 transcriptional activity   
WIP1 is encoded by the protein phosphatase magnesium-dependent 1 delta (PPM1D) 
gene, which was mapped to 17q22/q24, a hotspot that is observed to be amplified in 
breast, lung, pancreas, bladder, liver cancer and neuroblastoma (Li et al., 2002; Bulavin 
et al., 2002; Saito-Ohara et al., 2003; Hirasawa et al., 2003). Since p65 has an 
antiapoptotic role and mostly deregulated in cancer, we investigated if WIP1 
overexpression affects the p65 transactivation potential in human HeLa cells. We co-
transfected increasing concentration (0-2 μg) of WIP1 plasmid DNA with pGL3 vector 
control into HeLa cells, and constant levels of NF-κB luciferase reporter construct, and 
treat the cells with IL-1. Using dual luciferase reporter assay, we measured the 
transactivation of p65 with a κB site linked to the luciferase reporter gene. Transfecting 1 
μg of WIP1 expression plasmid DNA in HeLa cells is sufficient to increase the mRNA 
levels of WIP1 4-fold as shown in Figure 3.4.1A and hence its protein expression. 
Overexpression of WIP1 in HeLa cells resulted in a decrease in the transactivation 
potential of p65 on its target gene promoter in a WIP1 dosage-dependent manner (Figure 
3.3A). Overexpressing 1 μg of WIP1 reduced the transactivation potential of p65 by 
almost 2.5-fold whereas doubling the amount of WIP1 overexpression to 2 μg further 
decrease the transactivation potential of p65 by another 2-fold. 
A parallel experiment was done to investigate the expression of the endogenous NF-
κB target genes such as IL-8 and TNFα in HeLa cells. Overexpressing WIP1 in HeLa 
cells has a negative effect on the endogenous IL-8 and TNFα mRNA expression in a 
WIP1 dosage-dependent manner. The effect of overexpressing 1 μg of WIP1 in HeLa 
cells is not as dramatic as doubling the amount of WIP1 overexpression to 2 μg whereby 
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the expression of TNFα mRNA was reduced to an impressive 6-fold (Figure 3.3B), while 
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Figure 3.3      
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Figure 3.3 Overexpression of WIP1 reduces p65 transcriptional activity. 
HeLa cells were co-transfected with expression plasmid encoding WIP1, vector control 
pGL3 basic vector plasmid, 0.5 μg NF-κB luciferase reporter plasmid and 0.2 μg renilla 
plasmid according to material and methods. 48 hours after transfection, the cells were 
stimulated with 2 ng/ml of IL-1 for 12-16 hours. A) Luciferase activity of NF-κB 
activation was measured according to manufacturer’s instructions. Endogenous mRNA 
expression of TNFα (B) and IL-8 (C) was measured in real-time PCR using gene-specific 


















Chapter 3 WIP1 phosphatase negatively regulates p65 transcriptional activity 79
3.4 WIP1 regulates NF-κB activation and phosphorylation of p65           
       on serine 536       
 
 Consistent with the results in the WIP1 knockout MEF and WIP1 deficient mice, 
reducing endogenous WIP1 protein levels using lentivirus in HeLa cells by 30% (as 
measured by densitometric quantification of the western blot autorad X-ray film shown in 
Figure 3.4.2A) resulted in the activation of p65 as shown by the time kinetics of IκBα 
phosphorylation (and subsequent degradation) in response to TNFα induction and an 
increase in phosphorylated p65 (Figure 3.4.2B), and the expression of the transcript of its 
target genes IL-8 and TNFα (Figure 3.4.2 C & D). This result suggested that a small 
amount of WIP1 protein knockdown by 30% is sufficient to increase p65 phosphorylation 
on serine 536 (Chew et al., 2009). 
 Since the reduction of WIP1 in HeLa cells enhances p65 phosphorylation and 
transcription of its target genes, we investigated if overexpression of WIP1 would bring 
about an opposite effect. As shown in Figure 3.4.1A, the overexpression of WIP1 by 4-
fold and the induction of WIP1 mRNA by TNFα resulted in the reduction of p65 
phosphorylation when HeLa cells were treated with TNFα (Figure 3.4.1D). The reduction 
of p65 phosphorylation occurred upon 30 min of TNFα treatment and diminished greatly 
by 60-90 min. The measurement of WIP1 mRNA in HeLa cells in Figure 3.4.1A was 
done as an indication of transient overexpression of WIP1 protein because the antibody 
for WIP1 do not work well in HeLa cells. Next, we extended our investigation to other 
human cancer cell lines. In a human WIP1 inducible Saos-2 cells (Figure 3.4.1 E & F), 
we observed a reduction in the phosphorylation of p65 upon 30 min of TNFα treatment, 
and the kinetics of diminishing p65 phosphorylation happen in a similar fashion in both 
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the HeLa and Saos-2 cells (45-90 min TNFα treatment). Since the phosphorylation of p65 
can lead to the recruitment of transcriptional co-activators to enhance transcription of NF-
κB target genes, we investigated if the transcription of NF-κB genes were abated in WIP1 
overexpressing cells. As seen in Figure 3.4.1 B and C, overexpressing WIP1 result in the 
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Figure 3.4.1   
A     
                               
 
 





C           
   
 
Chapter 3 WIP1 phosphatase negatively regulates p65 transcriptional activity 82
  Figure 3.4.1 
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Figure 3.4.1 WIP1 regulates NF-κB activation and phosphorylation of p65 on serine   
536.   
1 μg of either WIP1 expression plasmid or vector control (pcDNA3.1) plamid was 
transfected into HeLa cells per well (6 well plate). A) WIP1 overexpression in HeLa cells 
was quantified by measuring WIP1 mRNA transcript in real-time PCR using gene-
specific primers. B & C) NF-κB activation was ascertained through the measurement of 
the transcription of its target gene, IκBα and TNFα in control and WIP1 overexpressing 
HeLa cells treated with 10 ng/ml of TNFα for 90 min. Data is the mean S.D. of two 
samples in one experiment representative of two independent experiments. E) Saos-2 
cells expressing doxycycline-inducible WIP1 was treated with 5 μg/ml doxycycline for 0, 
8, 16 and 24 hours to induce overexpression of WIP1. Detection of phosphorylated p65 
on serine 536 in (D) WIP1 overexpressing HeLa cells and (F) Saos-2 expressing 
doxycycline-inducible WIP1 cells. Cells were pre-treated with 5 μg/ml doxycycline 
overnight, followed by 10 ng/ml of TNFα for 15, 30, 45, 60 and 90 min. Cellular protein 
was extracted using RIPA lysis buffer. Phosphorylated p65 and total p65 was analyzed 
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Figure 3.4.2 


















































                      
B      











Chapter 3 WIP1 phosphatase negatively regulates p65 transcriptional activity 85
Figure 3.4.2 
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Figure 3.4.2 Knock down of WIP1 increases activation and phosphorylation on    
                      serine 536 of p65.  
A) Endogenous WIP1 protein levels were knocked down using lentivirus in HeLa cells 
and quantitated using a densitometer (Bio-rad laboratories). B) Control and WIP1 
knockdown HeLa cells were treated with 10 ng/ml of TNFα for 15, 30, 45, 60 and 90 
min. Treated cells were harvested and lyzed in RIPA lysis buffer. Phosphorylated p65, 
total p65 and total IκBα proteins were analyzed using whole cell lysates in western blot. 
Anti-actin was used as a loading control. C & D) NF-κB activation was ascertained 
through the measurement of the transcription of its target genes, IL-8 and TNFα in real-
time PCR using gene-specific primers. Data is the mean S.D. of two samples in one 
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3.5 NF-κB target genes are regulated in a p38 MAPK dependent and independent 
manner    
 
p38 MAPK is responsible for the indirect phosphorylation of histone H3 
surrounding the promoters of  NF-κB target genes, therefore promoting the transcription 
of these genes in inflammation. p38 MAPK can also positively affect the transactivation 
potential of NF-κB indirectly via the phosphorylation of MSK1 and IKK. Thus, we 
investigated if p38 MAPK affect NF-κB phosphorylation and its target genes in wildtype 
and p38 MAPK knockout MEF. As shown in Figure 3.5.1A, TNFα treatment did not lead 
to activation of p38 (as measured by by threonine 180/tyrosine 182 phosphorylation) in 
the p38 MAPK knockout MEF. The phosphorylation status of p65 on serine 536 was 
unaffected by the absence of p38 MAPK as seen in the p38 MAPK knockout MEF, and 
the kinetics of p65 phosphorylation was comparable to that of the wildtype MEF. We 
screened a panel of  NF-κB target genes (Figure 3.5.1 B & C) in the p38 MAPK 
knockout MEF and found that genes like IL-6, IRF1 and ICAM were expressed normally 
in WT MEF but completely abolished in p38MAPK knockout MEF . On the contrary, the 
mRNA levels of TNFα, IκBα and MCP1 were expressed in the p38 MAPK knockout 
MEF like as in wildtype MEF. 
In view that the WIP1 phosphatase can dephosphorylate p38 MAPK and 
inactivate p38 MAPK, we check if the effect of WIP1 on the phosphorylation of p65 and 
the transcription of p65 target genes was due to its direct effect via p38 MAPK. If WIP1 
is acting on p65 through p38 MAPK, phosphorylation of p65 should decrease when 
WIP1 siRNA HeLa cells are treated with p38 MAPK inhibitor SB202190. SB202190 
inhibits p38 MAPK activity without affecting its phosphorylation, consistent with the  
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inhibitor’s known mechanism of action, mainly inhibiting p38 MAPK by binding to the 
ATP site in p38 MAPK (Dmitrieva et al., 2002).  The phosphorylation of p65 in the 
WIP1 siRNA HeLa cells treated with p38 MAPK inhibitor remain the same as in 
wildtype HeLa cells (Figure 3.5.2 A & B). The mRNA levels of IL-6 and IL-8 were 
elevated in WIP1 siRNA HeLa cells but the addition of a p38 MAPK inhibitor 
diminished IL-6 and IL-8 mRNA expression level (Figure 3.5.2C), whereas the gene 
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Figure 3.5.1 
B  p38 MAPK dependent genes 
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Figure 3.5.1    
C  p38 MAPK independent genes 
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Figure 3.5.1 NF-κB target genes are regulated in a p38 MAPK dependent and p38 
MAPK independent manner. 
A) WT and p38 MAPK knockout MEF were treated with 10 ng/ml of TNFα for 15, 30, 
45, 60 and 90 min. Treated cells were harvested and lyzed in RIPA lysis buffer. 
Phosphorylated p65 and total p38 MAPK were analyzed using whole cell lysates in 
western blot. Anti-actin was used as a loading control. B & C) NF-κB activation was 
ascertained through the measurement of the transcription of its target genes, IL-6, IRF1, 
ICAM, TNFα, IκBα and MCP1 in real-time PCR using gene specific primers. Data is the 
mean S.D. of two samples in one experiment representative of two independent 
experiments. WT and p38 MAPK knockout MEF were treated with 10 ng/ml of TNFα for 
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Figure 3.5.2 
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Figure 3.5.2 
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Figure 3.5.2 NF-κB target gene independent of p38 MAPK regulation.  
A & B) Control and WIP1 siRNA HeLa cells were treated overnight with 10 μM p38 
MAPK inhibitor SB202190 (p38I), and subsequently with 10 ng/ml TNFα for 15, 30, 45, 
60 and 90 min. Phosphorylated p65 on serine 536 and p38 MAPK threonine 180 and 
tyrosine 182 were analyzed in western blot using specific phospho-antibody. C & D) NF-
κB activation is ascertained in WIP1siRNA HeLa (HWKD) cells by measuring NF-κB 
target genes IL-6, IL-8 and TNFα in real-time PCR using gene-specific primers. Data is 
the mean S.D. of two samples in one experiment representative of two independent 
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3.6 PP2A phosphatase does not synergize with WIP1 in regulating NF-κB dependent   
       transcription  
 
 The PP2A phosphatase has been the most well-documented phosphatase that 
dephosphorylates p65, and its signaling component in the NF-κB signaling pathway by 
far. We investigated the possibility of a co-operation of PP2A and WIP1 phosphatase in 
dephosphorylating p65, and “switching off” p65 activation. Okadaic acid is a toxic 
polyether fatty acid produced by dinoflagellates, and is a potent inhibitor of PP2A. Ozaki 
et al. demonstrated that 100 nM of okadaic acid enhances phosphorylation of p65 on 
serine 536, the consequential translocation of NF-κB from the cytosol to the nucleus, and 
the stimulation of NF-κB transcriptional activity in luciferase assay in osteoblastic MG63 
cells (Ozaki et al., 2006). Although treating HeLa cells with 25 nM of okadaic acid is a 
concentration that is lower than what is published in the literature, it is still effective in 
stimulating the phosphorylation of p65 on serine 536. We observed an increment in p65 
phosphorylation in okadaic acid treated cells as compared to control cells (Figure 3.6A). 
Next, we treated WIP1 siRNA HeLa cells with 25 nM okadaic acid to see if inhibiting 
PP2A would bring about an increment of p65 phosphorylation. As shown in Figure 3.6B, 
adding okadaic acid to WIP1 siRNA cells do not enhance p65 phosphorylation, therefore 
there may not be a synergistic effect of PP2A and WIP1. Next, we investigated if the 
inhibition of PP2A in WIP1 siRNA HeLa cells has any effect on p65 transcription. 
Inhibiting PP2A in HeLa cells brought an increase in the mRNA transcript of IL-6, IL-8 
and TNFα as compared to untreated cells. However, inhibiting PP2A in WIP1 siRNA 
HeLa cells did not result in a further increase in the transcription of these NF-κB target 
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genes when compared to wildtype HeLa cells treated with okadaic acid or WIP1siRNA 
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Figure 3.6 
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Figure 3.6 PP2A does not synergize with WIP1 to regulate NF-κB dependent 
transcription. 
WIP1 siRNA (B) and wildtype HeLa (A) cells were pre-treated with 25 nM of okadaic 
acid for 12-16 hours before stimulating the cells with 10 ng/ml TNFα. Treated cells were 
lyzed in RIPA lysis buffer and whole cell lysates were analyzed with p65 serine 536 
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Figure 3.6 PP2A does not synergize with WIP1 to regulate NF-κB dependent 
transcription. 
(C) Sybr green real-time PCR of NF-κB target genes in wildtype (H) and WIP1siRNA 
HeLa (HWKD) cells pre-treated with okadaic acid (OK), and subsequently treated with 
TNFα for 90 min using gene-specific primers. Data is the mean S.D. of two samples in 














Chapter 3 WIP1 phosphatase negatively regulates p65 transcriptional activity 102
3.7 WIP1 dephosphorylates p65 directly on serine 536 
 So far, we have shown that WIP1 has an effect on p65 phosphorylation on serine 
536 in vivo. We investigated if WIP1 can directly dephosphorylate p65 on serine 536 in 
vitro, in phosphatase assay. We overexpressed FLAG-tag wildtype p65, and p65 serine 
536 to alanine mutant (S536A) in HeLa cells. We stimulated the activation and 
phosphorylation of p65 with TNFα, and immunoprecipated activated p65. The protein G 
agarose beads containing bound, activated p65 was incubated with purified WIP1 
recombinant protein in phosphatase buffer. As shown in Figure 3.7A lane 2 and 4, WIP1 
efficiently dephosphorylates endogenous and activated p65 on serine 536. The p65 
S536A mutant do not get phosphorylated at serine 536 and therefore dephosphorylation 
by WIP1 do not occur (lanes 5-8). Levels of phosphorylated p65 on serine 468 were 
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Figure 3.7 
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Figure 3.7 WIP1 dephosphorylates p65 directly on serine 536. 
 A) p65 wildtype and S536A mutant expression plasmid were transfected into HeLa cells 
at 10 μg per 10 cm plate. 48 hours after transfection, the cells were treated with 10 ng/ml 
of TNFα for 30 min. After treatment, the cells were harvested and lyzed in IP lysis buffer. 
1 mg of whole cell lysates was immunoprecipitated with rabbit anti-FLAG antibody. The 
protein G agarose beads containing immunoprecipitated mutant and activated FLAG-tag 
wildtype p65 were incubated with recombinant WIP1 protein in phosphatase buffer 
containing MgCl2 for 60 min. The in vitro phosphatase reaction was terminated with SDS 
loading buffer. Phosphorylated p65 on serine 536 and serine 468 were analyzed in 
western blot using specific phospho-antibody. The immunoprecipitation of p65 was 
verified with mouse anti-FLAG antibody. B) A model based on our studies demonstrate 
that NF-κB activating stimuli induces p38 MAPK pathway activation. WIP1 negatively 
regulates NF-κB in two ways.  Firstly, WIP1 regulates NF-κB by negatively regulating 
p38 MAPK which has a positive effect on NF-κB target genes IL-6 and IL-8. Secondly, 
WIP1 negatively regulates NF-κB directly by dephosphorylating NF-κB and affecting its 
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3.8 Discussion 
 Constituitively activated, phosphorylated p65 has been observed in many cancer 
cells. Since p65 is a transcription factor for many antiapoptotic genes, it is possible that 
constituitive action of p65 render cancer cells resistant to apoptotic stimuli. p65 undergo 
a cycle of phosphorylation and dephosphorylation event regulated by kinases like MSK1, 
PKA, PKC, RSK1, CKII and IKK and phosphatase PP2A in human cancer cells. The role 
of phosphatases is to dephosphorylate active p65, to switch off constituitive p65 in cancer 
cells so that cancer cells can respond to apoptotic stimuli. One possibility of constituitive 
p65 activation may be due to disruption of phosphatase activity, and hence basal 
transcriptional activation of p65, which is often observed in cancer. 
 The WIP1 phosphatase is often overamplified in cancer, and thus its role as an 
oncogene has been implicated in cancer. It has been postulated that when WIP1 is highly 
expressed in cancer, dephosphorylates the tumour suppressor p53, whereby p53 is still 
intact in this cancer cells. WIP1 therefore disrupt p53 proapoptotic function in cancer 
cells. We have investigated if WIP1 can affect p65 function in apoptosis in cancer cells 
through p65 target gene regulation, in particular antiapoptotic genes. To our surprise, 
there is no difference in the mRNA expression of antiapoptotic genes such as Bcl-XL and 
XIAP, between control cells and WIP1 overexpressing or deficient cells (data not 
shown). Instead, we found differences in the mRNA expression of inflammatory 
cytokines, which are NF-κB target genes. Therefore, other than its oncogenic role in 
cancer, we propose that WIP1 has a role in negatively regulating inflammation by 
affecting NF-κB phosphorylation and hence the transcription of inflammatory cytokines. 
Deficiency of WIP1 leads to the increase of phosphorylation of p65 on serine 536 in the 
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kidneys of WIP1 deficient mice probably suggesting p65 role in inflammation is more 
apparent in the kidneys (see Figure 3.2B). 
 By far, the serine/threonine family of protein phosphatase PP1, PP2A and PP2B 
(calcineurin), and PP2C has been implicated in negatively regulating the NF-κB signaling 
pathway by dephosphorylating IKK and IκBα. Only PP2A has been shown to physically 
associate with, and dephosphorylate p65 (refer to section 1.6.2). Here, we showed that the 
deficiency of endogenous WIP1 phosphatase, which belongs to the PP2C family of 
serine/threonine protein phosphatases, resulted in the activation and phosphorylation of 
the p65 subunit of the NF-κB transcription factor, while its overexpression is sufficient to 
reduce the activation of p65. However, unlike PP2A, the physical interaction between 
WIP1 and p65 is probably transient, similar to the transient interaction of WIP1 with p53 
(Lu et al., 2005), because we did not pull down p65 when we overexpressed WIP1 or 
when we do the reverse in co-immunoprecipitation experiment (data not shown). It is 
interesting to note that treatment of HeLa control cells with TNFα for 15 min showed an 
induction and up-regulation of phosphorylated p65 but this up-regulation was not 
observed at later time points e.g. 30-90 min when compared to the sustained 
phosphorylation of p65 in WIP1siRNA cells at these time points (Figure 3.4.2B). It is 
highly possible that the treatment of the control cells with TNFα may result in the 
induction and up-regulation of WIP1 which in turn dephosphorylates p65 in the later time  
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points, whereby TNFα induction and up-regulation on WIP1 occurs at the transcriptional 
level in the control cells as shown in Figure 3.4.1A, although we have not shown 
experimentally that TNFα up-regulates WIP1 at the protein level.  
 p38 MAPK co-ordinates and influence the expression of many proinflammatory 
cytokines such as IL-6, IL-8 and TNFα through indirect histone phosphorylation in a 
promoter-specific manner. We show that p38 MAPK do not affect phosphorylation of 
p65 and the lack of p38 MAPK causes an abolishment of IL-6 mRNA expression in 
MEF, whereas in the p38 MAPK WT MEF, the expression of IL-6 occurs as usual 
(Figure 3.5.1B). A marked increase in IL-6 and IL-8 mRNA expression was observed in 
WIP1siRNA HeLa cells when compared to control HeLa cells. The addition of p38 
MAPK inhibitor in WIP1siRNA HeLa cells caused a 2-fold decrease on IL-6 and IL-8 
mRNA expression when compared to untreated WIP1siRNA HeLa cells (Figure 3.5.2C). 
This result suggest that the expression of these cytokines is dependent on p38 MAPK, 
and that the presence of WIP1 inactivates p38 MAPK, possibly through 
dephosphorylation of p38 MAPK in these HeLa cells, resulting in the decrease of IL-6 
and IL-8 mRNA expression. Interestingly, the expression of TNFα mRNA is the same 
with or without the addition of p38 MAPK inhibitor (Figure 3.5.2D) in the WIP1siRNA 
HeLa cells, suggesting the expression of TNFα mRNA, unlike IL-6 and IL-8, is not 
dependent on p38MAPK. Therefore, WIP1 negative regulation on TNFα mRNA 
expression is not going through the p38 MAPK signaling pathway, but is definitely a 
direct effect of WIP1 on p65. The significance of this result is that WIP1 negatively 
regulates p65 in two ways. Firstly, WIP1 negatively regulates p38 MAPK which has a 
positive effect on NF-κB target genes IL-6 and IL-8 and secondly, WIP1 negatively 
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regulates NF-κB directly by dephosphorylating NF-κB and thus affecting its target gene 
TNFα. (see Figure 3.7B). 
 Since PP2A may compensate for the lack of endogenous WIP1 phosphatase 
activity in HeLa cells, we inhibited PP2A activity in the WIP1 siRNA HeLa cells using 
okadaic acid. We showed that inhibiting PP2A did not lead to a further increase in the 
expression of TNFα mRNA (Figure 3.6C), and therefore, we investigated if the 
regulation of the expression of TNFα mRNA is solely dependent on WIP1. True enough, 
we show that WIP1 can dephosphorylate p65 on serine 536 through in vitro phosphatase 
assay (Figure 3.7A). The phosphorylation of p65 on serine 536, a critical residue that lies 
in the transcriptional activation domain (TAD), is necessary for p65 transcriptional 
activation. Hence WIP1 dephosphorylation of p65 on serine 536 thus resulted in the 
reduced transcription of p65 target gene TNFα. WIP1 by dephosphorylating serine 536 
on p65, may disrupt the recruitment of transcriptional co-activator such as p300, 
necessary for p65 acetylation, and its full transcriptional activation, and the assembly of 
the transcriptional machinery on κB sites on the TNFα promoter.  
 The deregulation and overproduction of TNFα has been implicated in human 
diseases such as autoimmue disorders like rheumatoid arthritis, systemic lupus 
erythematosus, multiple sclerosis, sepsis and cancer. Therefore, TNF production has to be 
tightly regulated in order to prevent the onset of such human diseases. TNF can be 
regulated transcriptionally and post transcriptionally. Transcriptional activation of TNFα 
occurs through the binding of NF-κB to the TNFα promoter, while post-transcriptional 
regulation of TNFα occurs by modulation of its mRNA stability (Sun et al., 2007). 
Therefore consistent with its nuclear localization, WIP1 can negatively modulate NF-κB 
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transcriptional activity through post-translational modification on p65 to affect TNFα at 
the transcriptional level, in response to TNF receptor stimulation. WIP1 thus provide a 
negative feedback signal to control the overproduction of TNFα, in situation where the 
TNF receptor is over stimulated in an autocrine fashion. Here, we reported a novel 
finding, and we propose a model whereby WIP1 negatively regulates the classical NF-κB 
signaling pathway, and may thus serve as a potential useful therapeutic target in the 
treatment of chronic inflammatory diseases, whereby the overproduction of TNFα is due 
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Figure 3.8 Model of WIP1 phosphatase modulating the NF-κB signaling 
pathway  
WIP1 can negatively modulate NF-κB transcriptional activity on the TNFα promoter 
in the nucleus in response to TNF receptor stimulation, and hence generate a negative 
feedback loop in the overproduction of TNFα. 
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3.9 Conclusion and future directions 
 The investigation of WIP1 phosphatase in regulating the p65 subunit of NF-κB is 
a fruitful and rewarding venture. In vivo, the lack of WIP1 phosphatase in MEF result in 
the increase basal level of NF-κB target genes IκBα, MIP1α and TNFα, and p65 is also 
observed to be constituitive phosphorylated on serine 536, particularly in the kidneys of 
WIP1 deficient mice. We also showed that deficiency of WIP1 phosphatase resulted in 
the activation of NF-κB in HeLa cells, and its overexpression is sufficient to reduce the 
transcriptional activity of NF-κB on its target genes in HeLa cells. We also showed that 
the serine/threonine protein phosphatase PP2A does not synergize with WIP1 to 
negatively regulate p65. In vitro, we showed that WIP1 phosphatase negatively regulated 
TNFα transcriptionally, independently of p38 MAPK, through the direct 
dephosphorylation of p65 on serine 536. 
 Stress responses such as IR and UV-C activate NF-κB. Since WIP1 phosphatase 
is initially discovered in WMN burkitt’s lymphoma cells, and is induced by IR and UV 
(Fiscella et al., 1997), there exist a possibility of WIP1 negatively regulating p65 in 
respect to DNA damage responses. We have not explored this possibility, although this 
avenue of future research work is of great significance especially when the ATM kinase 
(a downstream target of WIP1) is often activated via the stress induced pathway and 
ATM is required for IR induced IKK-NF-κB pathway (Li et al., 2001). WIP1 may 
indirectly negatively regulate NF-κB via ATM or by directly dephosphorylating p65 in 
respect to DNA damage responses. Right now, we have only shown WIP1 effects on p65 
via the classical NF-κB signaling pathway, future work could be carried out to investigate 
if WIP1 can affect p65 via the stress induced pathway. 
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 Multiple kinases like MSK1, PKA, PKC, GSK-3β, RSK1, CKII and IKK 
phosphorylate p65 at various sites such as serine 276, 311, 529 and 536 (Figure 3.9). The 
closer residue to serine 536 on p65 is serine 529, and the postulated serine 535 on p65. 
The phospho-antibody used to detect the phosphorylation of p65 on serine 536 may also 
recognize these sites. We are synthesizing phosphopeptides containing phosphorylated 
serine 529 (PNGLLpSGDEDF), serine 536 (GDEDFSpSIADMD), serine 311 
(YETFKpSIMKKS) and positive control p38 MAPK (TDDEMpTGpYVAT) for in vitro 
phosphatase assay (phosphatase kinetic studies), to corroborate that WIP1 indeed 
dephosphorylates p65 on serine 536 only.  
 Since IKK is known to phosphorylate p65 on serine 536, upon TNFα induction, 
this may placed IKK in close proximity to WIP1. Hence in vitro phosphatase assay of 
WIP1 using activated IKK as a substrate can be carried out to investigate if WIP1  
dephosphorylate IKK, and hence result in the reduction of phosphorylation of p65 on 
serine 536. This experiment is designed to investigate and confirm WIP1’s direct effect 
on serine 536 of p65 and serves to confirm the reduction of phosphorylated p65 is not due 
to the consequence of WIP1 dephosphorylating IKK in close proximity.  
 We have also successfully identified NF-κB target genes that are independent of 
p38 MAPK regulation in p38 MAPK knockout MEF such as TNFα, IκBα and MCP1, in 
particular TNFα, which WIP1 phosphatase directly regulates. It would be worthwhile to 
engage in the search for more NF-κB target genes whose mRNA expression is directly 
regulated by WIP1 phosphatase, to show that WIP1 phosphatase can regulate other 
cytokine gene expression in addition to TNFα in the immune system at the transcriptional 
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level. Microarray studies could be performed to do a genome wide screening of NF-κB 
target genes that is regulated directly by WIP1 phosphatase. 
 The phosphorylation on p65 leads to the recruitment of transcriptional co-
activator like p300 and the transcriptional machinery to NF-κB target gene promoters. 
Since WIP1 dephosphorylate p65, it would be ideal to perform co-IP experiments of p65 
and p300 in WIP1 overexpressing HeLa cells, to show that WIP1 overexpression may 
lead to reduction in p65 phosphorylation and p300 interaction and recruitment to NF-κB 
target gene promoters, chromatin remodeling, and hence the reduction in the mRNA 
expression of NF-κB target genes. To gather more supporting evidence, experiments such 
as chromatin immunoprecipitation assay (CHIP) could be performed to show less binding 
of p65 to its target gene promoters in WIP1 overexpressing HeLa cells. 
 NF-κB is a transcription factor crucial for the production of proinflammatory 
cytokines in innate immunity. Macrophages are immune cells that form the first line of 
defence in the innate immune response, and they are the main source of TNFα when the 
body experience an infection. Since we show that WIP1 negatively regulates p65 target 
gene TNFα upon TNF receptor stimulation, we would also like to investigate the 
physiological relevance of WIP1 phosphatase regulation on TNFα, or other yet unknown 
inflammatory cytokine production in peritoneal macrophages isolated from wildtype and 
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    Figure 3.9 
     Phosphorylation sites on p65 
                                                     
                                                         262                                                   276                                                290 
    Human: LQAPVRVSMQLRRPSDRELSEPMEFQYLP 
                           Mouse: LQAPVRVSMQLRRPSDRELSEPMEFQYLP   
       262                                                  276                                                290 
    
                                       297                                                 311                                             225 
     Human: RIEEKRKRTYETFKSIMKKSPFSGPTDPR 
     Mouse: RIEEKRKRTYETFKSIMKKSPFNGPTEPR 
       297                                                311                                              225 
    
                                                           454                                                 468                                                 482 
      Human: LGNSTDPAVFTDLASVDNSEFQQLLNQGI 
     Mouse: LGNSTDPGVFTDLASVDNSEFQQLLNQGV 
                                         453                                                 467                                                   481 
      
                                                           515                                                 529               535 536                                             550 
     Human: PAPLGAPGLPNGLLSGDEDFSSIADMDFSALLSQIS 
     Mouse: APTPLGTSGLPNGLSGDEDFSSIADMDFSALLSQIS 
                                       513                                               527                533 534                                             548 
 
    
 
Figure 3.9 Phosphorylation sites on p65 
The amino acid sequence of full-length mouse (in blue print) and human (in black print) 
p65. The phosphorylation sites of p65 are depicted in red. 
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3.10 Perspective 
The fundamental processes in terminating NF-κB activation is not entirely 
understood, and is an area of intense research. Most efforts in abrogating NF-κB 
activation has focussed on targeting IKK by using IKK inhibitors or IκB super repressors 
which are resistant to degradation, and thus forestall NF-κB disassociation from IκBα. In 
mammalian cells, a natural form of terminating NF-κB activation exist via a negative 
feedback loop, through the synthesis of IκB mRNA upon NF-κB translocation to the 
nucleus to bind DNA and activate transcription of its inhibitor, the IκB gene.   
Kinjyo et al and Nakagawa et al showed that Suppresor of signaling-1 (SOCS-1) 
is a negative regulator of NF-κB, and decreases NF-κB transcriptional activity in LPS 
signaling (Kinjyo et al., 2002; Nakagawa et al., 2002). Multiple inflammatory organ 
diseases, hallmarks of LPS-associated disease, have been observed in SOCS-1 knockout 
(KO) mice. LPS forms an integral part of gram negative bacteria and can provoke a life-
threatening condition called toxic shock. Chronic repeated exposure to LPS cause a 
transient increase in the threshold of endotoxin tolerance as a way of protection from 
endotoxic shock syndrome by down-regulating TLR4 and decreased NF-κB activation. 
The authors simultaneously reported reduced tolerance for LPS in SOCS-1 knockout 
cells, and the overexpression of SOCS-1 in cells exhibited a dose-dependent attenuation 
of NF-κB action in reporter gene assay. The phosphorylation of IκBα which leads to its 
degradation and an indicator for the activation of NF-κB was also observed to be 
enhanced in SOCS-1 deficient murine peritoneal macrophages. These experimental 
evidences further support that SOCS-1 protein is a negative regulator of NF-κB. 
Chapter 3 WIP1 phosphatase negatively regulates p65 transcriptional activity 116
IKK1 is an essential kinase in the NF-κB alternative pathway that regulates the 
development and maintenance of secondary lymphoid organs. Macrophages that lack 
IKK1 have higher efficiency in the phagocytic clearance of E.coli K-12 as compared to 
wild type macrophages. LPS-induced IKK1 mutant macrophages have low levels of IκB 
proteins, elevated gene expression and production of proinflammatory cytokines and 
chemokines like TNFα, MIP1α, MCP1 and COX2. Moreover, IKK1 mutant macrophages 
have accelerated IκBα degradation upon LPS stimulation and most probably is due to the 
kinase hyperactivity in the IKK complex lacking IKK1 (Li et al., 2005; Lawrence et al., 
2005). Experimental data has therefore shown IKK1 as a negative regulator in the NF-κB 
classical pathway. 
In this section, we report the identification of a novel and direct negative regulator 
of the p65 subunit of NF-κB which is WIP1 phosphatase, thus adding it to a list of 
negative regulators of NF-κB signaling, which include the above mentioned SOCS-1 and 
IKK1. The importance of such a negative regulation by WIP1, is that WIP1 action on 
NF-κB is direct, in modulating NF-κB signaling, to regulate the expression of the 
proinflammtory cytokine, TNFα. Steed et al., had used structure-based design 
therapeutics to engineer variant TNF protein that form heterodimers with native TNF that 
do not bind TNF receptors, and hence unable to activate the TNF receptor pathway by 
means of sequestration as a possible means of anti-inflammatory biotherapeutics (Steed 
et al., 2003). The significance of our studies provided another avenue of an anti-
inflammatory biotherapeutics, other than preventing the live firing of TNF receptor 
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4.1 Introduction 
 The structure of the chromatin is influenced by acetylation which is dependent on 
the activities of HATs and HDACs. HDACs are chiefly involved in the repression of 
gene transcription by removing charge-neutralizing acetyl groups from the histone lysine 
tails resulting in the compaction of the chromatin structure. The “closed” structure of the 
chromatin prohibits the accessibility of transcription factors, transcriptional co-activators, 
and the replication machinery from binding to the DNA promoters, and therefore, inhibits 
gene transcription. Four classes of mammalian HDAC have been identified and they are 
involved in modeling the structure of chromatin. Class I HDACs consist of HDAC 1, 2, 
3, and 8, and class II HDACs consist of HDAC 4, 5, 6, 7 and 9. The third class of 
HDACs consist of SIRT1-7 which is homologues of yeast and mouse Sir2 and is 
insensitive to the HDAC inhibitor trichostatin A (TSA) and vorinostat/suberoylanilide 
hydroxamic acid (SAHA). All class I and II HDACs are zinc-dependent enzymes and 
class III HDACs require NAD+ for their enzymatic activity (Blander and Guarante, 
2004). Class I HDACs are primarily localized in the nucleus and ubiquitously expressed, 
while class II HDACs can be primarily cytoplasmic but able to migrate between 
cytoplasm and nucleus, and are tissue-restricted in expression (Xu et al., 2007). Class IV 
HDACs are represented by HDAC11, which like yeast Hda1 similar 3, has conserved 
residues in the catalytic core region shared by both class I and II enzymes (Gao et al., 
2002). 
 In non-hodgkin’s lymphoma, the LAZ3/BCL6 is overexpressed and functions as a 
transcriptional repressor through the recruitment of HDACs, leading to lymphoid 
oncogenic transformation (Dhordain et al., 1998). Given this example of the 
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physiological importance of inhibiting HDACs, the rationale of utilizing HDAC 
inhibitors in the treatment of leukaemias is relevant. Although the mechanism of HDAC 
inhibitors are not completely understood, inhibiting HDACs bring about at the cellular 
and molecular level, the accumulation of acetylated histones and transcription factors 
(which can also be acetylated by HATs), reactivation of epigenetically silenced tumour 
suppressor genes, cell cycle arrest and apoptosis in cancer. HDAC inhibitor induced cell 
death include apoptosis by the extrinsic pathway through the up-regulation of death 
receptors Fas and FasL, Trail and its receptor DR-5 in a mouse model of acute 
promyelocytic leukemia (APL) induced by valproic acid (Insinga et al., 2005); apoptosis 
by the intrinsic pathway via the release of cytochrome c (Bolden et al., 2006), AIF and 
Smac/DIABLO from the mitochondrial intermembrane space (Rosato et al., 2006; Ruefli 
et al., 2001), and activation of caspase-9 (Bolden et al., 2006) and via reactive oxygen 
species (ROS)-facilitated cell death (Ungerstedt et al., 2005). 
 The classes of compounds discovered as HDAC inhibitors include: short chain 
fatty acids/aliphatic acids (for example, 4-phenylbutyrate and valproic acid), hydroxamic 
acid (Oxamflatin, SAHA and TSA), bezamides (MS-275), and cyclic tetrapeptides 
(depsipeptide, trapoxin, and apicidin) (Marks et al., 2001). In general, HDAC inhibitors 
have been employed in the treatment of cancer due to their anti-tumourigenic activity on 
cancer cells but not on normal cells, unlike chemotherapy which kill both cancer and 
normal healthy cells. Hydroxamic acid such as TSA was initially developed as an 
antifungal agent, has a potent inhibitory action on class I and class II HDACs, inhibiting 
HDACs at micromolar or nanomolar concentration compared to other HDAC inhibitors 
where their effective concentration is at the millimolar range. In addition, TSA also has a 
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longer half life in vivo and bioavailabilities when compared to other HDAC inhibitors 
(Johnstone, 2002). In this section, we investigated the global expression of genes in 
human cancer cells treated with TSA using DNA microarray to look for interesting genes 
and to study their functions and signaling pathways. 
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 4.2 Concentration and time course studies of TSA treatment on   
        HCT116, Jurkat and U937 human cancer cells 
 It was reported that TSA can inhibit histone deacetylases at nanomolar 
concentration (Johnstone, 2002). We did a titration studies on a range of human cancer 
cell lines such as colorectal cancer cells (HCT116), leukemia T-cell (Jurkat) and 
monocytic (U937) cells to test the toxicity of TSA. As seen in Figure 4.2.1A-D, the lethal 
concentration (LC50) is 100 nM for HCT116 and Jurkat cells at 24 hours, and the LC50 
remains at 100 nM in both cell lines after treatment for 48 hours while the LC50 for 
U937 is at 1 μM for 24 hours (Figure 4.2.1 E & F). Next, we investigated the effect of 1 
μM TSA on all three cell lines at various treatment times. Using sytox-hoechst staining, it 
was observed that the treatment of these cell lines with 1 μM TSA for 24 hours resulted 
in apoptosis (Figure 4.2.2). The treatment of these cells with 1 μM TSA for even bigger 
times of 36 hours and 48 hours is highly toxic leading to apoptosis of all cells (Figure 
4.2.3 A, C & E). Therefore, we then treated with 1 μM TSA at time points shorter than 24 
hours to determine the optimal time kinetics of the treatment. Figure 4.2.3 B, D and F 
showed the percentage of surviving cells upon treatment of cells with 1 μM of TSA for 4, 
8, 10, 12, 14, 16 and 24 hours. After these time course studies, we selected the TSA 
concentration at 1 μM and the treatment time of 0, 4, 8, 12 hours as the optimal 
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Figure 4.2.1  
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Figure 4.2.1 Concentration studies of TSA treatment on HCT116, Jurkat and U937 
cells.  
HCT116 (A & B), Jurkat (C & D) and U937 (E & F) cells were treated with 0.1, 1, 3, and 
5 μM TSA for 24 and 48 hours and cell survival for each concentration was measured 
using Wst-1. Data is the mean S.D. of three samples in one experiment representative of 
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Figure 4.2.2 
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Figure 4.2.2 Sytox-hoechst staining of HCT116, Jurkat and U937 cells treated with 1 
μM TSA for 24 hours.  
Control HCT116, Jurkat, and U937 and TSA-treated cells were stained with sytox- 
hoechst stain to visualize apoptotic cells. Necrotic cells (damaged and sytox-permeable) 
were stained green and apoptotic cells (hoechst-stained, condensed and fragmented 
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Figure 4.2.3 
A      B 
 
 
C      D 
 
 






Chapter 4 Microarray studies & functional analysis of genes regulated by TSA 126
Figure 4.2.3 Time course studies of TSA treatment on HCT116, Jurkat and U937 
cells. 
HCT116, Jurkat and U937 cells were treated with 1 μM TSA for 0, 8, 16, 24, 36 and 48 
hours (A, C & E) and for 0, 4, 8, 10, 12, 14, 16 and 24 hours (B, D & F). Cell survival for 
each time point was measured using Wst-1. Data is the mean S.D. of three samples in one 
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4.3 Microarray analysis of genome wide effects in gene expression in response to  
      TSA treatment 
To study the effect of inhibiting HDAC on the regulation of gene expression, we 
used spotted oligonucleotide arrays representing 19, 000 gene set (Genome Institute of 
Singapore). HCT116, Jurkat, and U937 cells were treated with 1 μM of TSA for 0, 4, 8 
and 12 hours. The expression of 723 genes changed significantly when using the criteria 
of 2-fold cut off after TSA treatment. 111 out of the 723 genes displayed progressive 
changes in gene expression across the four time points, out of which 36 genes are up-
regulated and 75 genes are down-regulated. Among the 111 genes, we selected a few 
interesting genes for further verification by real-time PCR (Figure 4.3). These genes were 
genes involved in the NF-κB pathway like lymphotoxin β receptor (LTβR), interleukin 2 
receptor (IL-2R), IRAK1 and NF-κB1 (precursor of IκB). Interestingly, we also noticed 
apoptotic genes to be regulated in all 3 cells lines. They were clusterin, RAD9, BNIP3L, 
STAT3, PDCD2, Bid, RAD21 and PIGPC1 (Perp). We also verified the expression of 
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  Figure 4.3 Microarray analysis of genome wide effects in gene expression in    
     response to TSA treatment. 
     Clustering analysis depicting genes that are regulated by TSA. Cluster and treeview     
     were used to cluster genes showing progressive changes (2-fold in 4 time points) in    
     gene expression. Red and green represent up-regulation and down-regulation,  
    respectively, relative to the untreated control (black). The intensity of colour correlates  
    to the magnitude of change. Only selected genes are shown. 
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4.4 TSA inducible genes 
 We classified the genes that have expression that exhibited progressive changes 
across the four time points into TSA inducible and TSA repressed genes. These TSA 
inducible genes were observed in all three cell lines in the microarray analysis and they 
are clusterin, STAT3, RAD9 and BNIP3L. However, upon validation by real-time PCR, 
the transcript of these genes was not regulated across the three cell lines similar to that in 
the microarray. We found that clusterin was up-regulated in HCT116, Jurkat and U937 
cells, STAT3 was up-regulated in HCT116 and U937 cells and not in Jurkat, Bnip3L and 
RAD9 were up-regulated only in U937 cells. On the contrary, Perp which was shown to 
be repressed in the microarray was up-regulated in Jurkat cells in the RT-PCR (Figure 
4.4A). We confirmed by real-time PCR that the fold change was indeed more than 2-fold, 
as reflected in the microarray data (Figure 4.4 B & C). Furthermore, we also examined 
these genes at the protein levels. As seen in Figure 4.4D, the levels of clusterin protein 
were increased in HCT116, Jurkat and U937, the levels of STAT3 were increased in 
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Figure 4.4 
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 Figure 4.4 TSA inducible genes.  
RT-PCR (A), real-time PCR (B) and western blot (D) of TSA induced genes in the 
microarray. Actin was used as a loading control in the western blot. RT-PCR and real-
time PCR were performed using gene-specific primers and the fold of inducibility by 12 
hours TSA treatment for the real-time results was tabulated (C). In (B), data is the mean 
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4.5 TSA repressed genes   
 The TSA repressed genes that exhibited progressive changes across the four time 
points in all three cell lines on the microarray are LTβR, IRAK1, RAD21, Bid, PDCD2, 
IL-2R, and NF-κB1. Interestingly, a number of these genes such as LTβR, IL-2R, 
IRAK1 and NF-κB1 are associated with the NF-κB signaling pathway. Although the 
above mentioned genes are reflected on the microarray to be down-regulated, only LTβR, 
IRAK1, RAD21, Bid, IL-2R and NF-κB1 down-regulation could be validated by real-
time PCR. IRAK1 and Bid were down-regulated across all three cell lines, lymphotoxin β 
receptor in HCT116 and U937 cells, IL-2R in Jurkat and U937 cells, NF-κB1 in HCT116 
and Jurkat cells, and RAD21 was down-regulated only in HCT116 cells (Figure 4.5.1 & 
4.5.2). Interestingly, the protein expression of Bid and RAD 21 were found not to be 
induced nor repressed as assessed by western blot, even though their transcripts were 
verified to be down-regulated in real-time and RT-PCR, strongly indicating that these 2 
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Figure 4.5.1 
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Figure 4.5.1  
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Figure 4.5.1 TSA repressed genes.  
RT-PCR (A), real-time PCR (B) and western blot (D) of TSA repressed genes in the 
microarray. Actin was used as a loading control in the western blot. RT-PCR and real-
time PCR were performed using gene-specific primers and the fold of repression by 12 
hours TSA treatment for the real-time results was tabulated (C). In (B), data is the mean 
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Figure 4.5.2 TSA repressed genes that are in the NF-κB signaling pathway.  
Real-time PCR of genes that were repressed are receptors (A), adaptor (B) and precursor 
IkappaB (C) in the NF-κB signaling pathway in the microarray using gene-specific 
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4.6 Role of Clusterin in TSA induced apoptosis 
 Clusterin (CLU), also known as apoliprotein J, has been implicated in various 
physiological processes like carcinogenesis and tumour growth, cell cycle regulation, and 
apoptotic cell death. Induction of clusterin mRNA and protein levels have been 
consistently detected in various human malignancies such as bladder, breast, colon, lung, 
and kidney tumour, and also in cells and tissues undergoing stress. There are two 
clusterin isoforms in human cells, a secretory form (sCLU) which is believed to be 
prosurvival and the nuclear form (nCLU) which is proapoptotic (Leskov et al., 2003). As 
seen in Figure 4.4 D, the secreted form of clusterin is a glycosylated protein of 80 kDa, 
and appears to have two different protein bands of 40 kDa (α and β subunit) and 60 kDa 
(full-length, uncleaved form) when analyzed on a SDS-PAGE under reducing conditions 
(Yang et al., 1999). In contrast, the 49 kDa nuclear form of clusterin is synthesized from 
a second AUG start codon resulting in an alternative spliced nCLU mRNA. In response 
to ionizing radiation (IR), it becomes modified to a 55kDa proapoptotic form, which 
translocates to the nucleus in MCF-7 cells (Leskov et al., 2003). 
  In our microarray, real-time PCR, RT-PCR and western blot data, we saw a 
consistent up-regulation of clusterin in all three cell lines. Since clusterin has been 
implicated in apoptosis, we seeked to investigate if the induction of clusterin by TSA 
participate in apoptotic events in these cells. Firstly, we investigated the inducibility of 
the proapoptotic form of nCLU in HCT116, Jurkat, and U937 cells treated with TSA for 
12 hours. We extracted the nuclear fraction of these treated cells and analyzed the 
expression of the nuclear form of clusterin by western blot. As seen in Figure 4.6.1A, 
there was no accumulation of clusterin in the nucleus when cells were treated with TSA. 
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Hence, it is highly probable that the induced expression seen resulted in the increased in 
the secretory form of clusterin. Next, we sought to elucidate if the sCLU is involved in 
apoptosis of the TSA-treated cell lines. We knocked down the expression of secretory 
clusterin using pre-designed siRNA oligos from Ambion. We selected siRNA 
oligonucleotides (ID numbers: 2566, 2568 and 2745) from the Ambion database and 
tested the efficiency of these oligonucleotides to silent the mRNA of clusterin. As shown 
in Figure 4.6.1B, oligo ID number 2566 and 2745 efficiently knocked down the 
expression of clusterin. Subsequently, these two oligo were utilized to elucidate the 
physiological effect of knocking down clusterin protein, with respect to TSA induced 
apoptosis. Intriguingly, the reduction in the protein levels of sCLU decreased the 
proportion of apoptotic cells as determined by sub-G1 phase of treated cells stained with 
PI (Figure 4.6.1C). Our results show for the first time, that sCLU, similar to nCLU, also 
has a proapoptotic function, since the reduction of clusterin levels resulted in lesser cell 
death. Next, we were interested to find out if the induction of clusterin gene expression 
upon TSA treatment was a direct effect of inhibiting HDAC or an indirect effect through 
the regulation of other genes by TSA. This is a relevant question since Tingan Chen et al. 
showed that the induced expression of clusterin in 5-flurouracil (5-FU) and anti-Fas 
antibody treated HCT116 cells is largely dependent on p21 since cells lacking p21 lacked 
induction of expression of clusterin upon similar treatment (Chen et al., 2004). In 
addition, they also showed that the treatment of p53-deficient HCT116 cells with 5-FU 
and anti-Fas antibody resulted in the overexpression of clusterin protein. Since the 
expression of p21 and p53 could be induced by TSA in cells (Johnstone, 2002), we 
investigated if clusterin up-regulation in TSA-treated cells was a consequence of p21 and 
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p53 inducible expression. To answer this question, we used HCT116 cells devoid of p21 
and p53, treated the cells with TSA and determined the expression of clusterin in these 
cells. The expression of clusterin protein was induced and the pattern of induction was 
similar to those of wildtype HCT116 cells (Figure 4.6.2 A & C). This suggested that 
clusterin expression in our model was independent of p21 and p53. We next investigated 
if clusterin-inducible expression required de novo protein synthesis. The expression of 
clusterin both in the basal and TSA-treated levels were sensitive to cyclohexamide 
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Figure 4.6.1     
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Figure 4.6.1  
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Figure 4.6.1 Secretory clusterin has a proapoptotic role in TSA induced apoptosis.  
A) Nuclear extracts from HCT116, Jurkat and U937 cells either untreated or treated with 
TSA for 12 hours. Nuclear form of clusterin, purity of cytoplasmic (C) and nuclear (N) 
extract were analyzed by western blot using anti-clusterin, anti-lamin (nuclear) and anti-
tubulin (cytoplamic) antibody. B) Reducing clusterin protein expression in HCT116 cells 
using pre-designed Ambion siRNA oligonucleotides. The expression of clusterin protein 
is validated in western blot and the membrane was stained with coomassie blue to show 
equal loading of protein sample. C) Apoptosis in clusterin siRNA HCT116 cells is 
measured using PI staining. Data is the mean S.D. of three samples in one experiment 
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Figure 4.6.2     
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Figure 4.6.2 
C 
0h     4h     8h     12h   0h    4h     8h    12h TSA (1 µM)






0h     4h      8h   12h    0h    4h    8h    12h TSA (1 µM)
HCT116 WT HCT116  p21-/-
 
 
E       
Clusterin
- - +              +     1 µM TSA (12h)











Chapter 4 Microarray studies & functional analysis of genes regulated by TSA 150
Figure 4.6.2 Increased clusterin expression is dependent on HDAC regulation. 
Up-regulation of the clusterin protein by TSA treatment is independent of p53 (A) and 
p21 (C). Actin was used as a loading control in the western blot. The protein levels of 
p53 (B) and p21 (D) in HCT116 cells is verified in western blot using p53 and p21 
antibody. (E) HCT116 cells were treated with or without cyclohexamide (CHX) and 
TSA, or both in combination. Clusterin protein and mRNA levels were analyzed in 
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4.7 Discussion 
  Microarray-based gene expression profiling of drug-treated cancer cells is a 
powerful tool to investigate the mechanism of action of anti-tumour agents, especially 
HDAC inhibitors which directly target the transcriptional machinery of cancer cells, 
hence altering the transcription of a subset of genes that control diverse molecular 
pathways, particularly those important for mediating apoptosis, and tumour growth 
suppression. In this section, we investigated the genes that are regulated by histone 
deacetylase and the molecular events involved. 
 Increase in histone acetylation is often observed in TSA-treated cells resulting in 
chromatin remodeling, and hence the accessibility of the transcriptional machinery to 
target genes, generally leading to enhance gene transcription. However, the gene 
expression profile of TSA-treated cancer cells were not all hallmarked by enhanced 
global transcription. Rather, we found distinct patterns of coordinated transcriptional 
changes, including repression of some genes in the microarray data. We identified in the 
microarray, genes in the apoptotic pathway (CLU, BNIP3L, Bid, Perp, PDCD2), DNA 
damage inducible signaling pathway (RAD9), cytokinesis (RAD21), mediators of 
cytokine signaling (STAT3), and genes associated with the transcription factor NF-κB 
pathway (LTβR, IRAK1, IL-2R and NF-κB1) that exhibited transcriptional changes. We 
verified selected genes by RT and real-time PCR. Some of these genes such as CLU, 
BNIP3L, PERP, RAD9 and STAT3 mRNA are reactivated, while Bid and RAD21 
mRNA are repressed in response to HDAC inhibition.  
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 HDAC inhibitors cause cell-cycle arrest in G1 and/or G2 phase, apoptosis or 
differentiation of cultured transformed cells. Normal cells undergo cell cycle checkpoints, 
and survive TSA treatment, while cancer cells can replicate their DNA and subsequently 
undergo apoptosis (Marks et al., 2001). RAD9 is a member of the family of cell cycle 
checkpoint RAD genes required for S phase (DNA replication) and G2 (DNA mitosis) 
checkpoints in response to DNA damage (Rhind and Russell, 1998; Stewart and Enoch, 
1996). The induction of RAD9 mRNA and protein in U937 cells by TSA may implicate 
its importance in the regulation of the cell cycle, and may play a role in cell cycle 
checkpoint in U937 cells. In addition, RAD9 has also been reported to have a 
proapoptotic role. RAD9 interacts with antiapoptotic Bcl2 family proteins Bcl2 and Bcl-
XL to trigger apoptosis (Komatsu et al., 2000). Therefore, RAD9 may promote apoptosis 
in U937 cells treated with TSA, but confirmation will require further investigation. 
 It is interesting to observe the induction of STAT3 in TSA-treated HCT116 and 
U937 cells. STAT3 is a transcription factor regulating cell-growth related genes, 
enhances transformation, and blocks apoptosis (Bromberg et al., 1999). STAT3 is 
acetylated on Lysine (lys) 685 upon cytokine treatment (Yuan et al., 2005). Lys 685 
acetylation is required for STAT3 to form stable dimers required for the transcription of 
its target genes. Hence, the induction and acetylation of STAT3 may be a mechanism of 
protecting TSA-treated cells against apoptosis. 
 We were able to verify the repressed RAD21 gene expression in the microarray 
analysis by RT and real-time PCR. However, the level of RAD21 protein remains 
unchanged upon TSA treatment. RAD21 is one of the cohesin subunit that holds sister 
chromatids together and required for appropriate chromosomal adhesion during mitotic 
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cell cycle and double-strand-break repair after DNA damage (Biggins and Murray, 1999; 
Nasmyth et al., 2000). It is currently unclear as to why the relief of histone deacetylation 
resulted in the repression of RAD21 transcription and even more intriguing that the 
RAD21 protein level is unaffected. The decreased gene transcription of RAD21 could be 
an indirect effect from the enhanced transcription of other transcription factors that 
regulate RAD21 gene expression. As for the unaltered protein level, it may be explained 
by the treatment time since the down-regulation of RAD21 transcript was only obvious at 
the 12 hour TSA treatment. A longer treatment time point may be necessary to see an 
effect at the protein level especially if the protein is highly stable. 
 Since TSA can induce apoptosis in cancer cells, one would expect the activation 
of proapoptotic genes and repression of antiapoptotic genes in cells treated with TSA. It 
was interesting to note that the transcript for the proapopotic gene, Bid was suppressed in 
all three cancer cells by TSA but the protein expression remained stable throughout TSA 
treatment. It is unclear at present the contribution of Bid to TSA induced apoptosis. 
Perhaps, other proapoptotic Bcl2 family members may play a more dominant role in the 
apoptotic response of TSA treatment. 
 We further extended our analysis to establish the role of clusterin in TSA induced 
apoptosis because of the up-regulation of clusterin observed in the microarray analysis 
that was validated by RT-PCR, real-time PCR, and western blotting in HCT116, Jurkat 
and U937 cells. In Figure 4.6.2E, we show sCLU is a target gene of HDAC regulation. 
Interfering with protein translation of clusterin using cyclohexamide in HCT116 cells led 
to a dramatic reduction of clusterin protein, and hence strongly suggesting that de novo 
protein synthesis of clusterin is required. 
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 Clusterin is an enigmatic protein with two isoforms (sCLU and nCLU) showing 
distinct functions and subcellular localization. 1, 25-Dihydroxyvitamin D3 (1, 25 (OH)2 
D3) could inhibit cell proliferation, induce apoptosis in cancer cells, and increased 
expression of sCLU in benign prostate hyperplastic cells (Crescioli et al., 2004). It was 
speculated that sCLU is a stress-associated cytoprotective protein that is up-regulated in 
response to various apoptotic triggers. On the flip side, transient expression of clusterin in 
Myc-transduced clonocytes decreased cell accumulation, and knockdown of clusterin via 
antisense RNA in neoplastic epidermoid cells enhanced proliferation. In addition, 
Thomas-Tikhonenko et al. showed in a DMBA/TPA induced skin carcinogenesis mouse 
model that clusterin could inhibit skin tumour development as they observed an increase 
in the mean number of papilloma in clusterin null mice compared to wild type (Thomas-
Tikhonenko et al., 2004). Conflicting data exhibiting both proapoptotic and antiapoptotic 
properties of clusterin are currently present in the field and are dependent on cell type and 
stimulus (Table 2). Here, we showed that sCLU gene expression is up-regulated upon 
TSA induced apoptosis, supporting the role of clusterin as a proapoptotic protein in our 
model (Figure 4.6.1C). 
 The nuclear form of clusterin is 49 kDa, is synthesized from a second AUG start 
codon of an alternative spliced CLU mRNA, in cells exposed to ionizing radiation (IR). 
nCLU then becomes modified to a 55 kDa proapoptotic form and translocate to the 
nucleus in MCF-7 cells. The mutation of the NLS in the C-terminal of nCLU abrogated 
nCLU ability to induce apoptosis, thus suggesting that the localization of nCLU in the 
nucleus is essential for its apoptotic function (Leskov et al., 2003). If nCLU plays a part 
in TSA induced apoptosis, one would expect an increase in the translocation and 
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subcellular localization of nCLU in the nucleus upon TSA treatment. We showed in 
Figure 4.6.1A, that basal protein level of nCLU in the nucleus, was not further increased 
upon TSA treatment. Therefore, our data suggested that nCLU may be redundant, and 
that sCLU is the dominant player in TSA induced apoptosis in HCT116 cells.
 Besides nCLU, ionizing radiation can also induce the expression of sCLU in 
MCF-7 and HCT116 cells. Since ionizing radiation can induce both isoforms of clusterin, 
intracellular regulation of the expression of both isoforms may exist for cells to determine 
if they were to survive or to undergo apoptosis. Criswell et al showed that lack of p53 
augmented CLU de novo synthesis after IR exposure, and further demonstrated that p53 
repressed sCLU protein, not nCLU in mediating apoptosis in their study (Criswell et al., 
2003). In Figure 4.6.2A, we showed that this regimen of p53 repression of sCLU did not 
occur in TSA-treated HCT116 cells, because cells lacking p53 did not show a decrease or 
abolishment of sCLU protein levels upon treatment with TSA. This data suggested that 
the regulation of sCLU and nCLU isoforms by TSA is entirely different from that of IR, 
and further supported our observation that TSA induced the expression of sCLU to 
activate apoptosis, independently of nCLU.  
 The mechanisms that differentially regulate the clusterin isoforms so that sCLU 
activates apoptosis (or compensates for nCLU) in TSA-treated cells require further 
investigation. It can be speculated that treating cells with TSA may lead to signal 
transduction pathways and activation of upstream molecules which can differentially 
regulate the two isoforms by 1) preventing the induction and processing of the 
alternatively spliced nCLU, 2) suppressing basal nCLU propapoptotic function in the 
nucleus, and 3) molecules which inhibit the translocation and accumulation of nCLU in 
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the nucleus by sequestering nCLU in the cytoplasm upon TSA induction and thus 






Table 2 Function of clusterin in different cell types 
The proapoptotic or antiapoptotic function of clusterin is distinct in different cell 
types and dependent on the genetic background of the cell type and the nature of 
the stimulus/factor that induces its expression. (Reproduced with permission from 
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4.8 Conclusion and future directions 
 The search for genes that are regulated by the HDAC inhibitors using 
oligonucleotide microarray is a tedious, yet challenging venture. TSA induces apoptosis 
in human colon cancer (HCT116), T-cell leukemia (Jurkat) and monocytic U937 cells. 
We have shown that the relief of HDAC inhibition, and hence chromatin remodeling can 
bring about changes in the expression of a number of genes, resulting in the induction of 
genes such as clusterin, STAT3, RAD9, Perp and BNIP3L, and repressed the expression 
of genes like LTβR, IRAK1, RAD21, Bid, IL-2R and NF-κB1 in human cancer cells. 
Specifically, TSA up-regulated the expression of the secretory form of clusterin, 
promoting apoptosis in HCT116 cells. 
 The pleiotrophic effects of HDAC inhibitors provided an advantage as an 
anticancer agent because most cancer cells have multiple gene defects, affecting several 
pathways that regulate cell proliferation and survival. Through genome wide screening, 
we found several targets belonging to several different signaling pathways to be regulated 
by the HDAC inhibitor, TSA. Although we have shown that the relief of HDAC 
inhibition did result in the derepression of the clusterin gene expression, analysis of the 
clusterin promoter using CHIP assay to show the acetylation of histone in this region, 
hence the remodeling of chromatin leading to the accessibility of transcription factors and 
the transcriptional machinery to the clusterin promoter will be necessary to confirm 
HDAC direct effects on clusterin gene expression. Another possible candidate in 
inducing a proapoptotic response in TSA-treated cells which is worth investigating is 
RAD9. Studies involving the overexpression or siRNA knockdown of RAD9 will be 
necessary to investigate its transcriptional reactivation by TSA, and if such reactivation 
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represses expression of antiapoptotic protein like Bcl2 and Bcl-XL leading to apoptosis in 
TSA-treated cells. 
HDAC inhibitors are good agents to treat inflammation-associated malignancies 
because they have been reported to reduce the production of cytokines in various 
inflammatory diseases, and are able to induce apoptosis in cancer cells. TSA has been 
observed to inhibit IL-8 expression in colonic epithelial cells which suggest that it is 
effective in the treatment of ulcerative colitis through increased histone acetylation and 
reduced production of proinflammatory cytokines by the intestinal epithelium (Yin et al., 
2001; Huang et al., 1997; Gibson et al., 1999). TSA and another HDAC inhibitor, 
suberoylanilide hydroxamic acid (SAHA) also exhibited anti-inflammatory effects in 
vivo, by inhibiting IL-6, IL-10, IL-12 and IFN-γ production in MRL-lpr/lpr  mice, a 
model of systemic lupus erythematosis (SLE) (Mishra et al., 2003).  
TSA has also been reported to affect the functionality of NF-κB, a transcription 
factor responsible for the expression of many proinflammatory cytokines like TNFα, IL-
1, IL-2, IL-6 and IL-8. NF-κB is kept inactive, through interaction with the inhibitor of 
kappa B (IκBα), as a NF-κB-IκBα complex in the cytoplasm, and prevented from 
translocation to the nucleus to activate transcription. NF-κB activation is promoted by its 
disassociation from IκBα when IκBα undergo degradation upon stimulation with NF-κB 
activating stimuli such as IL-1, LPS and TNFα. TSA has been reported to inhibit 
constituitive NF-κB activation in a concentration dependent manner by increasing the 
stability of IκBα protein (Yin et al., 2001).  
Chapter 4 Microarray studies & functional analysis of genes regulated by TSA 159
Imre et al. also reported that the treatment of human non-small cell lung cancer 
(NSCLC) with TSA reduced TNF receptor mRNA and protein expression, and hence 
resulted in a reduction in IKK phosphorylation and the delayed phosphorylation of  IκBα 
in these cells when further treated with TNFα (Imre et al., 2006). These results suggested 
that HDAC inhibitors can cause TNF receptor down-regulation, triggering the 
desensitization of the NF-κB pathway. On the contrary, several groups have also reported 
the opposite effect of HDAC inhibitors in activating NF-κB through either direct 
acetylation or inhibiting HDACs that physically associate with NF-κB. In our microarray 
analysis, we reported a down-regulation of the LTβR (NF-κB alternative pathway), IL-
2R, adaptor IRAK1, and its precursor p105, NF-κB1 mRNA, all known to be associated 
with the NF-κB signaling pathway. Due to time constraint, we were not able to perform 
further analysis to establish the significance of the down-regulation of these genes upon 
TSA treatment. It will therefore be worthwhile to investigate if these targets are also 
affected at the protein level and if down-regulation of these genes could lead to the 
desensitization of the NF-κB pathway.   
Clusterin has been reported to negatively regulate NF-κB activity. Ectopic 
expression of clusterin in human neuroblastoma cells inhibited NF-κB activity through 
stabilizing IκBα. Absence of clusterin in MEF cause a reduction in IκBα stability, and a 
TNF-dependent increase in NF-κB activation, and transcription of  its target gene cIAP 
(Santilli et al., 2003). It is currently unclear if the induced expression of clusterin by TSA 
in HCT116 cells resulted in an attenuation of NF-κB activity and if the attenuation is due 
to an enhanced stability of IκBα. Hence, further experiment could be carried out to 
determine if the reduction of clusterin protein levels in TSA-treated HCT116 cells will 
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4.9 Perspective 
 Due to the pleiotrophic effect of HDACs, it is not possible to determine a single 
pathway to be solely involved in its anti-tumour effect. At the molecular level, we need to 
improve our understanding of the nature of the selectivity of HDAC inhibitors in 
alterating gene transcription as to why some genes get activated and some genes get 
repressed. HDAC inhibitors seem to selectively have an anti-tumourigenic effect on 
transformed cells while leaving healthy, normal cells intact. One possible reason for 
tumour cells being more sensitive to HDAC inhibitors than normal cells, perhaps is due 
to the presence of multiple gene defects. Moreover, SAHA inhibition of HDACs is 
rapidly reversible, this suggest that normal cells with less genetic defects may be able to 
compensate for HDAC inhibitors induced changes more effectively than cancer cells, and 
therefore are more resistant to HDAC inhibitor induced cell death (Marks and Breslow, 
2007). Perhaps HDAC inhibitors may offer a major therapeutic effect of targeting 
different signaling pathways by activating or repressing some gene promoters in tumour 
cells. The mechanism of healthy normal cells in evading the apoptotic effect of HDAC 
inhibitors still remains an area of intense research. 
  The deacetylation process does not occur only on histones. Non-histone protein 
substrate which may be deacetylated by HDACs includes DNA transcription factors like 
p53 and NF-κB, steroid receptors such as glucocorticoid receptor, transcription co-
regulator such as retinoblastoma protein (Rb), signaling mediators such as STAT3 and 
Smad7, chaperone protein such as HSP90 and structural protein such as α-tubulin (Xu et 
al., 2007). These HDAC substrates are either directly or indirectly involved in many 
biological processes such as gene expression, and regulation of cellular pathways of 
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proliferation, differentiation and cell death. Therefore, the effects of HDAC inhibitors 
may not only affect chromatin remodeling but tumour cell death may also be induced 
through the acetylation of non-histone protein substrates. For example, transcription 
factors such as p53 and p65 can also be acetylated which may result in the regulation of 
their transcriptional activities, either enhancing or inhibiting expression of their target 
genes. However, the precise effect of HDAC inhibitors on these two transcription factors, 
ultimately resulting in the suppression of cell growth and apoptosis is also unclear and 
worth investigating.  
 HDAC inhibitors exhibited synergistic anti-tumour effects with chemotherapeutic 
agents such as VP-16 (etopside), ellipticine, camptothecin, doxorubicin, cisplatin, 5-
fluorouracil, cyclophomamide (Kim et al., 2003), and TRAIL through the simultaneous 
activation of both the intrinsic and extrinsic apoptotic pathways (Rosato and Grant, 
2004), suggesting that the combination of HDAC inhibitors together with other 
chemotherapeutic agents can be attractive strategies in combating cancer. However, just 
like any other anti-tumour therapy, whereby resistance to apoptotic cell death occurs, 
resistance to the effect of HDAC inhibitor induced cell death have also been observed in 
prostate cancer cells (PC3) (Xu et al., 2006). Several candidate proteins that may confer 
resistance to HDAC inhibitor induced apoptosis includes the overexpression of Bcl2 
(Mitsiades et al., 2003), and peroxiredoxins that reduce ROS generation (Kang et al., 
1998). 
  While the activation of anti-tumour pathways, and the mechanisms of the 
resistance to HDAC inhibitors is not entirely clear, SAHA (vorinostat), which belongs to 
the hydroxamate family of HDAC inhibitor as with TSA, is the first HDAC inhibitor to 
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be approved by the Food and Drug Adminstration (FDA) for the treatment of cutaneous 
T-cell lymphoma (CTCL) (Carew et al., 2008). Understanding the molecular events and 
mechanisms underlying the resistance and sensitivity to HDAC inhibitors will therefore 
be beneficial to improving the efficacy of HDAC inhibitors, and in understanding the 
long-term use, as well as the side effects that may accompany the use of these promising 
drugs in the treatment of cancer. 
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